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The strategies contract research organizations (CROs) use to develop relationships with 
pharmaceutical/biotech company clients are not well defined but can bring drugs to 
market faster, safer, cheaper, and with an innovative approach to partnership and 
scientific collaboration. Grounded in Porter’s competitive advantage theory, the 
comparative advantage theory of competition, and the resource-based view of strategy, 
the purpose of this qualitative multiple case study was to explore the lived experiences of 
nine key senior level decision makers in the pharmaceutical, biotech, and CRO industries, 
selected using a stratified purposeful sampling technique, to determine the benefit of 
partnerships between the CRO and client. Data were collected using semistructured 
interviews, public company documents, current market research, and literature. The data 
were analyzed using Yin’s five-step data analysis process and Moustakas’s modified van 
Kaam method. Three themes emerged: defining a strategic/essential partnership, 
understanding the benefit of building a relationship, and the study director is an essential 
asset. By understanding the importance of business relationships, the intangible value of 
human capital, client relationships, and the significance of trust in maintaining 
relationships, business leaders can implement strategies that provide business advantage 
and competitive value throughout drug discovery/development. By understanding 
interactions required for success, partnerships between the CRO and client may lead to 
innovations in contracted pharmaceutical research that may not only help save lives but 
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Section 1: Foundation of the Study  
Following the economic recession of 2008, mergers and acquisitions, large 
pharmaceutical company (pharma) consolidation, and acquisition of 
biotechnology/biopharmaceutical companies by pharma created industry dynamics that 
resulted in corporate downsizing and economic uncertainty caused by the restructuring of 
the pharmaceutical research sector to streamline operations, reduce costs, and improve 
efficiencies (Green, 2009). To remain competitive, pharmaceutical research company 
leaders focused on the productivity of their research and development (R&D) 
investments (PAREXEL, 2013). 
Contract research organizations (CROs) were directly and adversely impacted by 
client consolidation and tight funding, resulting in overcapacity, pricing pressures, and 
project delays, all of which negatively affected revenue (Green, 2009). By improving 
process efficiencies and evaluating strategic opportunities and business engagement 
between the CROs and pharma, both industries stood to gain as the economy recovered 
(Green, 2009). Strategic relationships were part of rethinking of the traditional R&D 
paradigm at global pharmaceutical/biotech companies (Miller, 2013). Forward strategic 
thinking focused on the CRO assuming more responsibility through strategic 
partnerships. As a result, the strategic partnerships between pharmaceutical/biotech 
companies and CROs drove flexibility, reduced costs, and expanded expertise 
(PAREXEL, 2013). The objective of this research study was to explore the outsourcing 
methods used by biopharmaceutical and pharma companies in the preclinical research 
industry and understand current and future trends for strategic partnerships. 
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Background of the Problem 
The financial crisis of 2008 had a substantial negative budgetary impact on 
pharmaceutical biotechnology companies. Pharmaceutical and biotechnology companies 
found that because of downsizing and restructuring, they no longer had the expertise to 
perform scientific/research tasks that they previously accomplished in-house. As a result, 
outsourcing increased to supplement or replace the expertise no longer available 
internally (Getz, 2014). In 2018, the global biopharmaceutical R&D spending was 
projected to reach $172 billion. Approximately $112-117 billion was estimated to be 
allocated to the total drug development market opportunity (Bank of America Merrill 
Lynch, 2018). William Blair & Company representatives estimated more bullish total 
drug development spending of $124 billion in 2018, $130 billion in 2019, and $134 
billion in 2020 despite the impact of the COVID-19 pandemic on the industry (William 
Blair, 2020). Of the total CRO market size (i.e., 67% of global R&D spend), it was 
estimated that 29% of the drug development spend is outsourced to CROs (Bank of 
America Merrill Lynch, 2018). Growth in the CRO industry is interrelated to 
pharmaceutical and biotechnology company R&D spending. 
Similarly, CROs were adversely impacted by the same client consolidation and 
tight funding, resulting in overcapacity, pricing pressures, and project delays, all of which 
negatively affected revenue (Green, 2009). However, following this period, the demand 
for and importance of the CRO grew. Increased outsourcing to CROs resulted in a more 
integrated and coordinated engagement between the CRO and pharma (Getz, 2014). This 
qualitative study explored the experiences of key decision makers at 
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pharmaceutical/biotech companies and CROs to describe and understand the 
collaborative approach to science and business that has fostered the strategic partnership 
paradigm. 
Problem Statement 
Following the financial crisis of 2008, increased outsourcing to CROs resulted in 
a more integrated and coordinated engagement between the CRO and pharma (Getz, 
2014). In 2018, global R&D spending allocated to the total drug development market 
opportunity was projected to reach approximately $112-117 billion, of which the CRO 
market size (drug development spending that is outsourced and may involve strategic 
partnerships) was estimated to be approximately $33 billion (Bank of America Merrill 
Lynch, 2018). The general business problem was that the role preclinical CROs assume 
in strategic partnerships with their pharmaceutical/biotech company clients is not well 
defined. The specific business problem was that some leaders of CRO and 
pharmaceutical/biotech companies lack strategies to develop strategic partnerships in the 
drug discovery and development process (Harris Williams, 2014). 
Purpose Statement 
The purpose of this qualitative multiple case study was to explore the strategies 
that CRO and pharmaceutical/biotech leaders use to develop strategic partnerships during 
the drug discovery and development process. The targeted population consisted of nine 
key decision makers at pharmaceutical research companies (large and small pharma), 
biopharmaceutical research companies, and CROs in the United States, Europe, and Asia. 
The implications for positive social change include the potential to provide an efficient 
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and collaborative drug discovery and development process that may result in novel 
lifesaving compounds receiving regulatory approval and getting to market faster and 
safer. 
Nature of the Study 
A qualitative study explores possible shared elements and opinions from the 
independent inquiry of personal thoughts, attitudes, and perceptions of participants and 
provides an in-depth understanding of the social world by asking open-ended questions to 
learn about the social circumstances, experiences, perspectives, behavior, knowledge, and 
histories of those participants (Kelly, 2016; Ritchie et al., 2014). Researchers use 
quantitative research phenomena by testing a theory consisting of construct variables, 
which are analyzed by means of mathematically based methods (Barnham, 2015; Yilmaz, 
2013). Mixed methods research incorporates quantitative and qualitative elements and is 
appropriate for research that includes both types of data (Almalki, 2016; C. B. Gibson, 
2017). A qualitative research method was appropriate for this study because it provided 
an in-depth understanding of the lived experiences of the participants, derived from first-
person reports (Moustakas, 1994), to determine if strategic partnerships between the CRO 
and pharma have been mutually beneficial. 
I considered three research designs for a qualitative study examining business 
strategies: (a) case study, (b) ethnographic, and (c) phenomenological. A case study 
delineates a single individual, group, program, or event and concentrates intrinsically on 
it to learn more about a poorly understood situation, phenomenon, or real-world 
experience (Freeman et al., 2015; Njie & Asimiran, 2014). Ethnography describes a 
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culture’s characteristics through direct observation and interaction with participants 
(Mohajan, 2018). Although an ethnographic design would provide an in-depth 
description of the pharmaceutical industry’s culture, a more specific understanding of 
individual experiences and opinions is needed. Descriptive transcendental 
phenomenology allows a researcher to gain meaning from lived experiences, 
perspectives, and knowledge (Kelly, 2016; Moustakas, 1994) and to examine business 
strategies focused on strategic partnerships, but the sampling methodology and sample 
size lead to an ambiguity and randomness that results in less concentrated data that could 
make the scope of the research too broad (Njie & Asimiran, 2014). A case study focuses 
on the sample (i.e., sample size) that provides the most appropriate, in-depth and up-
close, detailed accounts of information by concentrating on the depth and quality of 
information obtained rather than the number of research participants (Njie & Asimiran, 
2014; Yin, 2014). As such, the multiple case study research design was determined to be 
the most appropriate for this qualitative study. 
Research Question 
What strategies do service providers (i.e., CROs) and pharmaceutical/biotech 
companies use to develop strategic partnerships during the drug discovery and 
development process? 
Interview Questions 
Listed below are the interview questions: 
1. What do you think the role of a CRO is in a strategic partnership during drug 
discovery and development? 
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2. What is your strategy in terms of deciding what work (i.e., projects, programs, 
etc.) is outsourced to a CRO? 
3. How would you describe a strategic partnership with a CRO during the drug 
development process? 
4. Describe the most important factors that influence your selection of a strategic 
partner (ranked from most important to least important). 
5. What do you think currently differentiates the preclinical CRO(s) that you 
have strategic partnership(s) with and were similar strategies used to develop 
that/those relationship(s)? 
6. As strategic partnerships evolve, what are your concerns considering your 
current partnerships/relationships and the expectations you have now and in 
the future? 
7. How do you measure the financial success of your outsourcing (strategic 
partnership, if applicable) project(s)? 
8. How do you assess and manage outsourcing (strategic partnership) risks? 
9. Describe the risk-sharing responsibilities/assumptions you currently have with 
your outsourcing partner. 
10. What else can you add regarding strategies service providers (i.e., Contract 
Research Organizations) and pharmaceutical/biotech companies use to 





The conceptual framework of this case study supported the proposition that the 
risk in strategic partnerships formed between CROs and biopharmaceutical and pharma 
companies is not shared and that facts demonstrating real benefit are difficult to identify. 
The objective of this study was to explore the beliefs held by leaders in such companies 
about the phenomenon of strategic partnerships and their effect on project outsourcing. 
The concepts and theories that shaped this study include the market-based view (MBV) 
of strategy outlined in Porter’s competitive advantage theory (Porter, 1980; Wang, 2014), 
the comparative advantage theory of competition (Hunt & Morgan, 1995), and the 
resource-based view (RBV) of strategy (Wang, 2014). The amalgamation of these 
theories provided the framework for this study. 
Porter’s (1980) competitive advantage theory described a strategy where firms 
identify activities that could provide the company a competitive advantage. A 
competitive advantage strategy can be evaluated in terms of cost leadership, 
differentiation, and focus (Porter, 1980). A company’s internal environment is the focus 
of the RBV of strategy allowing for competitive advantage and the resources (internal 
and external) needed to compete in the market (Wang, 2014). In this study, I explored 
how key business leaders within the preclinical pharmaceutical CRO arena apply the 
competitive advantage theory when developing strategic partnerships during the drug 
discovery and development process. 
The comparative advantage theory of competition proposes a set of foundational 
premises that explain key macro and micro phenomena better than neoclassical perfect 
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competition theory (Hunt & Morgan, 1995). Most salient to this study was the premise 
that humans in the role of both consumers of products and managers of companies are 
constrained in their self-interest seeking by considerations of what is right, proper, 
ethical, moral, and/or appropriate (Hunt & Morgan, 1995). In addition, Hunt and Morgan 
(1995) suggested that resources, categorized as financial, physical, legal, human, 
organizational, informational, and relational, are the tangible and intangible entities that 
enable a company to provide a service that has value for some market segment(s). 
Salavou (2015) suggested that strategies of low cost (cost leadership), differentiation, and 
focus define how a company develops an advantage with respect to competitors and how 
that company can develop relative merits in terms of performance outcomes. This study 
ascertained if strategic partnerships result in expected value and risk sharing, or if firms 
are inhibited by their self-interests and seek services outside an established strategic 
partnership. 
Operational Definitions 
CDC: The Centers for Disease Control and Prevention (CDC) is a United States 
federal agency under the Department of Health and Human Services headquartered in 
Atlanta, Georgia. The CDC works to protect public health and safety by providing 
information to enhance health decisions, and it promotes health through partnerships with 
state health departments and other organizations. The CDC is the United States' national 
public health institute and is a founding member of the International Association of 
National Public Health Institutes (CDC, 2015). 
9 
 
CRO: A contract research organization is a service organization that provides high 
profile support to the pharmaceutical and biotechnology industries in the form of research 
services (e.g., target identification and validation, lead identification and optimization, 
preclinical testing and research, clinical research, clinical trials management, and 
postmarketing surveillance) outsourced on a contract basis (Bonacci & Tamburis, 2016). 
IPO: An initial public offering is the first sale of stock by a private company to 
the public. IPOs are often issued by smaller, younger companies seeking the capital to 
expand, but can also be done by large privately-owned companies looking to become 
publicly traded. Companies often decide to go public to raise equity capital in order to 
fund company growth, finance R&D and capital expenditure, pay off existing debt, 
and/or gain greater visibility, stronger legitimacy and higher market value (Cirillo et al., 
2018) 
NIH: The National Institutes of Health (NIH), a part of the U.S. Department of 
Health and Human Services, is the nation’s medical research agency—making important 
discoveries that improve health and save lives (NIH, n.d.). 
USFDA: The Food and Drug Administration (FDA or USFDA) is an agency of 
the U.S. Department of Health and Human Services. The FDA is responsible for 
protecting and promoting public health through the regulation and supervision of food 
safety, tobacco products, dietary supplements, prescription and over-the-counter 
pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, 
medical devices, electromagnetic radiation emitting devices (ERED), veterinary products, 
and cosmetics (FDA, 2015). 
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VC: Venture capital (VC) is capital (equity financing) provided by investors 
(individuals, business angels, corporations, governments, pension funds, and/or venture-
capital funds) to small business and start-up firms that have potential high growth 
opportunities. Venture capital investments have a potential for considerable loss or profit 
but are generally designated for investors who seek to generate a positive return on 
investment (Gantenbein et al., 2019). 
Assumptions, Limitations, and Delimitations 
An assumption is an idea presumed to be true but that cannot be verified by the 
researcher (Dahan & Shoham, 2014). Gorylev et al. (2015) defined limitations as 
potential weaknesses or general methodological problems of a research study. 
Assumptions and limitations are conditions beyond the control of the researcher and 
outside of proposed constraints (Bailey, 2014; Bloomberg & Volpe, 2015). Delimitations 
relate to the phenomenon; they are both analytical and contextual and are restrictions that 
the researcher places to focus the scope of the study (Bloomberg & Volpe, 2015; 
Marshall & Rossman, 2016; Rule & John, 2015). 
Assumptions 
I assumed that the participant pool would be representative of the key decision 
makers in pharmaceutical and biotechnology companies. Although these key decision 
makers were identified by key market intelligence, the specific decision-making process 
within any given company may not be fully understood. It is possible that those identified 
as key decision makers were part of a more complicated process by which business 
strategy is the result of a collective and not any individual person. Also, I assumed that 
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the interview questions in this study would be answered truthfully and that the 
participants would be honest, forthright, cooperative, and available for/during the 
interview. 
Limitations 
Data accuracy and completeness was dependent on the level of participation by 
the participants and willingness to share company information and strategy. The results 
of the study were limited by the honesty and thoroughness of the participants’ responses, 
and interview participation was not guaranteed. The participants’ availability to respond 
to interview questions in sufficient detail or specific knowledge of the subject may have 
limited the results of the study. To maximize participation, most interviews geared 
toward business evaluation and trending are accompanied by a monetary honorarium/gift. 
Given the target sample size, providing a monetary enticement to maximize participation 
was not possible or was not allowed by some of the participants’ employers. As a result, 
survey participation may have been less than anticipated, and the sample size may have 
consisted of a limited number of participants adequate to establish validity but not able to 
offer a larger representation of the population (Bernard, 2013). However, a small sample 
size is a common limitation in the validation of any study, regardless of the research 
method (Flicke, 2014). The availability of documentation to support the participants’ 
interview responses may have limited the results of the study.  
Delimitations 
Delimitations are topics, boundaries, or restrictions that the researcher imposes 
prior to the inception of the study to narrow the scope of the research and which cannot 
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be controlled by the researcher (Bloomberg & Volpe, 2015; Marshall & Rossman, 2016; 
Simon & Goes, 2015). The study delimitations included restricted participant 
selection/participation of key senior level decision makers in competitor CROs (i.e., 
CROs in direct competition with my employer that may have had confidentiality 
concerns with providing information that could result in an actual or perceived business 
advantage/liability). The senior level participants who were interviewed were currently 
employed and were assumed to have the experience and breadth of knowledge required 
to provide in-depth responses to the interview questions; therefore, no additional 
eligibility criteria were required. 
Significance of the Study 
Contribution to Business Practice 
Understanding and improving existing company processes and evaluating 
strategic partnerships implemented between the pharmaceutical/biotech companies and 
preclinical CROs could result in business opportunities that may be mutually beneficial. 
Preferred provider arrangements have enabled global pharmaceutical/biotech companies 
to realize cost savings across several fronts including reducing their fixed operating costs, 
leveraging operating efficiencies, and enabling collection of research data quickly and 
accurately (Miller, 2013). 
Strategic partnerships have been portrayed as beneficial to the sponsor companies 
implementing them (Parrett, 2013). However, based on the ownership of risk by the client 
company, the true benefit associated with the partnership is unknown. By appropriately 
understanding the role each company has in the partnership and the risk each company 
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assumes, transparency is gained, and clearly defined expectations could improve business 
processes and practices. 
Implications for Social Change 
Strategic collaborations between the pharmaceutical research and contract 
research industries have the potential to bring new drugs to market faster, for less cost, 
and with improved efficiency because of an innovative approach to business partnership 
and collaboration (Green, 2009). Pharma companies and the biotech industry have 
increasingly been relying on the CRO to complete FDA required testing as part of the 
regulatory submission process (Banerjee & Martin, 2014). Methods for promoting 
strategic opportunities and business engagement between the CRO and pharma are 
needed in the atmosphere of client consolidation, decreased funding, pricing pressures, 
and project delays. To reduce the cost and time of drug development, some pharma 
companies have pursued R&D joint ventures and outsourcing (strategic partnership) 
strategies (Banerjee & Martin, 2015). Innovation management in CRO-pharma/biotech 
collaborations is possible by identifying the existence of different options within an 
organization to develop this collaborative innovation. Innovation relates to how an 
institution decides to develop this partnership and how efficiently it can produce products 
and services that are superior to its competition (Jeng & Pak, 2016). By understanding the 
mutual interactions that are required for improved success, strategic partnerships between 
pharmaceutical/biotech companies and preclinical CROs may lead to innovations in 
contracted pharmaceutical research that may not only help save lives but provide for a 
healthier and improved quality of life. These strategic partnerships have the potential to 
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help bring pharmaceutical drugs to market faster, cheaper, and with improved efficacy 
because of a clear understanding of the role each organization plays in the drug approval 
process, the assumed risk each organization assumes in the partnership, and the continued 
innovative approach to business partnership and scientific collaboration. 
A Review of the Professional and Academic Literature  
A literature review is a systematic way of collecting and synthesizing previous 
research conducted by scholars and practitioners to map and assess the research area 
motivating the aim of the study and justify the research question and problem (Snyder, 
2019). The research described in this literature review provided the background 
information necessary to explore and understand the strategies used to develop strategic 
partnerships in the drug discovery and development process. The literature review begins 
with an overview of the drug development process and how outsourcing has and 
continues to impact drug development and the role of the preclinical CRO. I discuss 
funding and investment trends in the pharmaceutical research industry, and describe how 
strategic partnerships with CROs can foster lucrative and opportune financial outcomes. 
Porter’s (1980) competitive advantage theory is explained, and the market-based view 
strategy and the resource-based view strategy are introduced. 
Corporate downsizing and economic uncertainty have caused the pharmaceutical 
research sector to restructure and streamline operationally, reduce costs, and improve 
efficiency (Green, 2009). Pharmaceutical companies have focused efforts on productivity 
from their R&D investments to remain competitive (PAREXEL, 2013). Pharmaceutical 
and biotech companies have increased their level of open innovation to improve drug 
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development timelines and reduce costs in drug development and commercialization by 
improving market capitalization and revenue growth rate (Michelino et al., 2015). The 
literature review includes the strategic partnership model and how this could impact 
competitive advantage, an analysis of outsourcing effects, risks, and rewards, recent 
outsourcing (i.e., CRO) trends during the 2020 global COVID-19 pandemic, and the 
future of outsourcing and the preclinical CRO strategic partnership strategy. 
Drug Discovery and Development 
The pharmaceutical drug discovery and development process is a challenging 
undertaking that can take approximately 10 to 15 years and cost $1.0 to $1.5 billion 
(Harris Williams, 2014). This process requires sophisticated technology and expertise. To 
identify one effective and safe drug, millions of potential compounds and molecules are 
screened (Patil, 2016). For every 5,000 to 10,000 potential drugs evaluated, ultimately 
only one will receive approval from the FDA (Harris Williams, 2014; see Figure 1). 
Given the time and costs associated with drug development, pharmaceutical and biotech 
companies have increasingly been outsourcing development and preclinical activities to 





Drug Discovery and Development Process 
 
Note. The drug discovery and development process is divided into four main phases: pre-
discovery, discovery (late discovery), preclinical, and clinical trials. A successful IND 
application requires that the drug company demonstrate reasonable evidence concerning 
safety of the potential candidate molecule. Adapted from “Contract Research 
Organization Industry Overview,” by Harris Williams & Company, 2014, p. 1. Copyright 
2014 by Harris Williams & Company. 
 
Outsourcing 
Outsourcing R&D processes has the potential to lead to cost reduction when 
implemented and conducted properly (Yerkic-Husejnovic, 2017). New outsourcing 
processes were put in place to ensure seamless workflows to accelerate delivery of new 
medicines to patients (Martin et al., 2017). When managed improperly, the outsourcing 
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process can add to operational costs, terminated agreements, and strategic loss of internal 
R&D growth (Yerkic-Husejnovic, 2017). Outsourcing knowledge-intensive activities to 
knowledge process organizations (KPOs) serves to reduce obstacles to the innovation 
process (Gupta et al., 2009). Pharmaceutical and biotechnology companies have 
generally engaged CROs on a project-by-project basis to manage costs and utilize 
internal resources more efficiently (PAREXEL, 2013). Outsourcing to CROs allows 
pharmaceutical companies to use only the internal resources that are required at any 
given time and subcontract the expertise that they would not usually employ in-house 
(PAREXEL, 2013). By strategically outsourcing specific activities, companies can 
depend on the expertise of the outsourcing partner, thereby reducing costs associated with 
having to introduce innovation. Therefore, these companies strategically benefit from the 
KPO/CRO core competencies, economies of scale and scope, and knowledge sharing and 
learning (Gupta et al., 2009). Increased efficiency, time-savings, and lower cost have 
been the expected outcome of integrated technologies and multifunctional alliances 
(Getz, 2014). By focusing on improving the efficiencies of existing processes and 
evaluating strategic opportunities, both industries (i.e., pharma and CROs) would expect 
to benefit. Both industries form closer ties and business integrations to theoretically build 
efficiencies and save money (Henderson, 2013). 
Traditional large or midsized companies have usually assumed responsibility for 
most of the pharmaceutical value chain from drug discovery/development through 
production, marketing, and sales. Hiring contract service providers during the past 20-25 
years resulted from the need to access an available and variable head count to adapt to 
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peak periods of drug development activity and to gain access to scientific expertise no 
longer available internally because of downsizing and other cost saving measures (Getz, 
2014). While large and midsized pharmaceutical companies gradually increased 
outsourcing efforts, in contrast, emerging pharmaceutical companies, biopharmaceutical 
and biotechnology early-stage start-up companies focused on select stages of the 
pharmaceutical value chain that required expertise and logistics that they did not have. 
This required an earlier, more integrated and coordinated engagement with a KPO/CRO 
(Getz, 2014). 
As use of outsourcing increased, pharmaceutical and 
biopharmaceutical/biotechnology companies implemented more integrated engagements 
with CROs to take advantage of expertise in terms of capabilities, technologies, 
experience, time/cost efficiency, and regulatory requirements (Getz, 2014). 
Representatives of Credit Suisse (2018) reported that 40% of respondents to a market 
survey indicated that more than half of their preclinical budget was outsourced to a CRO, 
of which nearly 75% of these represent small pharmaceutical or biotechnology 
companies. The amount of preclinical budget that is outsourced is an indication that 
smaller to midsized biopharmaceutical companies use CROs because they lack the 
internal infrastructure that larger pharmaceutical companies already possess. Small and 
midsized pharmaceutical and biotechnology companies expected a 4.1% and 6.5% 
increase in preclinical budgets in 2018, respectively, compared with a 3.3% increase 
expected for large biopharmaceutical companies (Credit Suisse, 2018). 
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CRO Industry Overview 
Pharmaceutical companies introduced cost saving initiatives to stabilize 
profitability levels and maintain operating margins with R&D being a core target (Harris 
Williams, 2014). During the economic recession beginning in 2008, CROs were directly 
and adversely impacted by client consolidation and tight funding, resulting in 
overcapacity, pricing pressures, and project delays, all of which negatively affected 
revenue (Green, 2009). Pharmaceutical companies shifted focus to late-stage R&D 
development to drive drugs to market and replace lost revenue (Harris Williams, 2014). 
This shift in focus to late stage R&D development resulted in decreased total R&D 
preclinical development spend of -25%, -8%, -4%, and -2% year-over-year growth from 
2009 through 2012, respectively (William Blair, 2018). However, as expected, total 
outsourcing to clinical CROs increased, and with increased outsourcing, a more focused 
engagement between the CRO and pharmaceutical companies was expected (Green, 
2009, William Blair, 2018). CRO outsourcing by pharmaceutical companies across all 
therapeutic areas and phases increased 44% between 2007 and 2011 (Henderson, 2013). 
The pricing pressure that early stage (preclinical) CROs experienced began to stabilize in 
2013 as capacity levels normalized because some large preclinical CROs closed capacity. 
Growth in the CRO market is interrelated to pharmaceutical and 
biopharmaceutical R&D spending and was expected to be driven by growth in R&D 
spending and increased outsourcing of R&D activities (Harris Williams, 2014). In 2017, 
William Blair & Company representatives estimated that total R&D spending was $145 
billion and would increase year-over-year by 5% to an estimate of approximately $152 
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billion in 2018 (William Blair, 2018). Of the total CRO market size (i.e., 67%), 
approximately 71% of the drug development spend was still performed in-house, while 
the remaining 29% was outsourced to CROs (Bank of America Merrill Lynch, 2018). 
R&D budgets were expected to grow an average of 1.8% and 2.1% year-over-year in 
2018 and 2019, and 3.0% year-over-year in 2020 (William Blair, 2018). Actual R&D 
spending is expected to grow in the low-to mid-single-digit range in 2021 despite the 
impact of the COVID-19 pandemic, increasing to above 5.5% in 2022 and 2023 (William 
Blair, 2020). 
In 2015, the outsourced preclinical market was estimated to be approximately 
$3.3 billion with an outsourcing penetration rate of approximately 47% and expected 4-
year compound annual growth rate (CAGR) of approximately 6% on average for 2016 
through 2020 (Harris Williams, 2014; Jefferies, 2015). William Blair & Company 
representatives estimated the outsourced preclinical development market to be $4.7 
billion for 2018 and $5.1 billion for 2019 representing a 9% and 10% year-over-year 
growth rate, respectively, and forecasted the market to be $5.6 billion in 2020 (William 
Blair, 2020). The increased growth estimated for 2019 and 2020 are the result of 
increased outsourcing of preclinical services as a result of the COVID-19 pandemic. 
Year-over-year growth is expected to be 9% for 2020, 8% for 2021, and 7% for years 






Outsourcing Outlook for 2016 – 2020 





(2016 – 2020) 
Credit Suisse $3.5B 53% 5% 
Jefferies $3.2B 42% 7% 
UBS $2.9B 44% 3% 
William Blair $3.9B 36% 8% 
    
Average $3.4B 44% 6% 
Note. Adapted from “CRO Industry Update,” by William Blair, 2015; and 
“Pharmaceutical Svcs. Part II: Growing Pie, Unless Someone Eats a Big Slice,” by 
Jefferies, 2014. 
 
The CRO has typically been a service provider delivering single or multiple tasks 
on a per-project basis (PAREXEL, 2013). This relationship has evolved to one of 
strategic partnership where the CRO provides single or multifunctional support for entire 
programs reaching various portions of a pharmaceutical/biotech company portfolio (Getz, 
2014). These strategic partnerships (i.e., multiyear, highly integrated engagements 
between pharmaceutical/biotech companies and CROs) were created to provide 
functional support for entire drug development programs (Brocair Partners, 2013). Large 
pharma experienced significant challenges associated with the threat of revenue loss due 
to patent expiries, slowing chemistry-based research, and regulatory (i.e., FDA) scrutiny 
as the result of serious adverse reactions noted for well-publicized commercialized 
compounds. Large pharma has become open to strategies that (a) commercialize 
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compounds faster and (b) lower the total cost of developing compounds to 
commercialization. These strategies along with the high-throughput capabilities and 
expertise possessed by CROs increased the willingness of large pharma to outsource 
more of their development work and responsibilities to CROs.  
Funding and Investments 
Venture capital investors do not expect emerging bio/pharma companies to 
commercialize their drug pipeline candidates on their own; rather they anticipate that a 
global bio/pharma company will acquire these companies or in-license the 
pharmaceutical candidate (Miller, 2017). In 2016, venture capital maintained a pace close 
to that seen in 2015 and nearly 60% higher than it was in 2012 (Miller, 2017). Venture 
biotech funding was down 6% y/y in the first quarter of 2018 following a 10% increase 
year-over-year in 2017 compared to 2016 (William Blair, 2018). Conversely, IPO biotech 
industry funding was up 30% y/y in the first quarter of 2018 following a 20% decline in 
2017 compared to 2016 (William Blair, 2018). Total biotech industry funding was up 
45% year-over-year in the first quarter of 2018 following 37% growth in 2017 (William 








  Contract research organization 
  Charles River  Covance WuXi 
Pharmaceutical company  Early stage/preclinical relationship 
Abbott    R 
Amgen   S R 
AstraZeneca  S  R 
Biogen Idec     
Bristol Myers Squibb  R  S 
Daiichi     
Eisai     
Elan     
Eli Lilly   R R 
GE Healthcare    S 
Gilead     
GlaxoSmithKline  R R R 
Johnson & Johnson    R 
Merck  S R R 
Novartis    R 
Otsuka     
Pfizer    R 
Roche/Genentech   R R 
Sanofi-Aventis   S R 
Takeda     
Note. R = relationships that have been verified through company filings/reports or 
information obtained from news articles, industry contacts, etc.; S = ‘Strategic’ 
partnerships/relationships. Adapted from “Pharmaceutical Svcs. Part II: Growing Pie, 





Business challenges emphasize the need for effective communication and 
knowledge dissemination, either between information systems or between people (Pappa 
et al., 2009). Open integration has been an objective for the adoption of technology and 
collaboration to leverage the benefits of strategic planning. These benefits include 
compatible, standardized, and interoperable systems; accessible and transparent data and 
information; shared governance, risk, and operating practices; dedicated staffing and 
reduced numbers of sponsor staff overseeing execution (Getz, 2014). Specific business 
models could foster this strategic engagement allowing for risk-reward sharing 
opportunities that afford lucrative and opportune financial partnerships. Some business 
relationships result in different levels of involvement. Tactical transactional relationships 
do not require the same degree of communication, governance, or detail as more 
transformational relationships. Strategic clinical research partnerships were expected to 
evolve away from transactional models toward integrated relationships that drive value 
through specific alignments and efficiencies (PAREXEL, 2013). Market survey data 
collected by Credit Suisse representatives (2018) indicated that the move toward strategic 
partnerships continues to be a sustainable trend with preferred strategic partnerships in 
place for 82% of respondents. 
Festel et al. (2010) analyzed the stimulation of innovation in the pharmaceutical 
industry through outsourcing of R&D activities within the drug discovery and 
development process. This outsourcing opportunity provides a collaborative partnership 
that creates efficiency and improves profitability. Miller (2010) reported that Eli Lilly 
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and Company formed strategic outsourcing relationships to help reduce its fixed cost 
structure while providing quality development and manufacturing services. Eli Lilly 
representatives indicated that the company recognized 20% savings on data management 
and monitoring (Parrett, 2013). However, there is evidence that cost savings were not 
materializing in these partnerships (Parrett, 2013). 
As strategic partnerships evolve, they should provide a strong foundation for 
pharmaceutical and biopharmaceutical companies and preclinical CROs to address key 
concerns and challenges that are apparent in present CRO-sponsor relationships. Key 
factors affecting current relationships are: 
• limited alignment of goal and objectives 
• inadequate number of go-to labs 
• high CRO employee turnover 
• revised study pricing resulting from incorrect cost estimates 
• inadequate and often untimely information sharing 
PAREXEL representatives (2013) found that industry executives viewed future 
changes in the strategic partnership model would need to be driven by greater 








PAREXEL representatives (2013) described clinical CROs that chose to engage 
in strategic partnerships would need to focus on achieving specific metrics such as 
quality and timeliness. Dedication was defined as the CRO’s commitment to the client’s 
results and success, and alignment with the company’s specific needs. Risk-sharing 
covers a wide range of activities including investment in operational efficiencies such as 
technology, processes, staffing, and time as well as financial incentives and penalties 
demonstrating that the CRO is vested in shared success. Value was driven by the 
expectation that the relationship would yield cost and operational efficiencies without 
sacrificing quality. The model also provided for better communication between the two 
partners and greater sharing of information and expertise resulting in understood 
transparency (PAREXEL, 2013). Credit Suisse representatives (2018) described a 
sustainable trend toward strategic partnerships for outsourcing needs. 
Strategic forward thinking should focus on the CRO assuming a greater up-front 
risk in the drug development process by forming strategic partnerships with pharma. This 
risk-sharing model ensures that the CRO is operationally or financially vested in shared 
success (PAREXEL, 2013). 
Competitive Advantage 
Porter’s (1980) competitive advantage theory describes a strategy where firms 
identify activities that could provide the company a competitive advantage. 
Competitiveness is the tactical strategy for achieving goals and outperforming 
competitors (Soloducho-Pelc, 2014). Caiazza et al. (2015) described a firms’ 
competitiveness as dependent on the creation of knowledge through internal investment 
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and adoption/adaptation of external knowledge created by other organizations. Industrial 
organization economists propose that competitive advantage is achieved if a company has 
a better value creating strategy (i.e., market position) not simultaneously implemented by 
concurrent or potential competition, while resource-based view researchers suggest that 
competitive advantage is the result of a company’s specific capital and specific 
capabilities (Huang et al., 2015; Liu & Huang, 2017; Wang, 2014; Whalen et al., 2016). 
These conceptualizations of competitiveness suggest that a service provider is perceived 
and evaluated in comparison to other providers (i.e., the competition) in the industry, and 
this perception likely contributes to customer loyalty (Baumann et al., 2017). Ultimately, 
competitiveness can drive customer loyalty and the level of competition (a market 
condition) moderates the relationship between service quality and customer loyalty 
(Baumann et al., 2017; Chen, 2015). 
Market-Based View 
Industry factors and the external market condition are the primary determinants of 
an organization’s performance in the MBV of competitive strategy (Porter, 1985; Wang, 
2014). Wang (2014) argued that in this model, the sources of value for the organization 
are linked to the competitive characteristics of the end-product strategic position and that 
position is the organization’s unique attribute that is different from the competition. The 
strategic position can be described as how an organization performs similar activities to 
other companies, but in very different ways (Wang, 2014). Profitability and performance 
are therefore tied directly to the structure and competitive dynamics of that specific 
industry (Schendel, 1994; Wang, 2014). In formulating strategy, companies often assess 
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competitive advantage based on the external competition using Porter’s (1985) five 
forces model (see Figure 2). This model consists of 
• barriers to entry; 
• threat of substitutes; 
• bargaining power of suppliers; 
• bargaining power of buyers; and 






Summary of Five Forces – Key Drivers 
 
Note. An industry structure framework is built around five competitive forces that can 
impact the sustainability of profits. This framework functions to explain profitability 
against bargaining and against direct and indirect competition. Adapted from 
“Competitive Strategy: Techniques for Analyzing Industries and Competitors,” by M. E. 





















Wang (2014) concluded that there is considerable diversity in how strategy is 
conceptualized and no clear consensus that any one view is correct. Obtaining a certain 
market position involves competitiveness and competitiveness is about the ability to 
create competitive advantage using the company’s internal or relational resources 
(Baumann et al., 2017; Wang, 2014). 
To create a competitive advantage, an organization must understand the benefit 
their product provides, the target market and target market needs, and who/what is the 
competition. An organization needs to have clear and specific goals, strategies, and 
processes to build sustainable competitive advantage. Porter (1985) outlined three ways 
organizations achieve a sustainable advantage: 
• cost leadership 
• differentiation 
• focus 
Cost leadership is an organizations ability to provide reasonable value at a lower price. 
Cost leadership is a competitive strategy aimed at maximizing profits by providing the 
best possible product with a low production cost resulting in a higher market share than 
the competition (Brett, 2018; Porter, 1985). Differentiation is achieved when an 
organization is able to deliver a better product than the competition. Brett (2018) 
described this strategy as an organization’s ability to charge higher prices (higher profit 
margin) based on a higher quality product, or the customer’s perception of a higher 
quality product, compared to the competition. An organization typically achieves 
differentiation through innovation, quality, and/or customer service. Focus describes the 
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ability for an organization to understand and service the target market better than the 
competition. Focus strategy has two variants: (a) cost focus, and (b) differentiation focus 
(see Figure 3). In cost focus, an organization looks for a cost advantage for a specific and 
targeted segment of the market, while in differentiation focus an organization looks to 
create a differentiated focus for a particular market segment (Brett, 2018). Porter (1985) 
suggested that the three strategies are approaches that an organization should consider 
when dealing with competition. If an organization attempts to combine an emphasis on 
low cost and differentiation and fails to develop one of the three strategies, they will 
likely experience below average profits and end up in a weak strategic position (Brett, 
2018; Porter, 1985). In some cases, an organization may not have sufficient capital and 
market share for the cost leadership approach or may not have the expertise to pursue a 
differentiation focus strategy (Brett, 2018). As a result, the organization will not be able 
to attract high-end customers and may lose them to other companies who are able to 
successfully differentiate (Brett, 2018; Porter, 1985). It is important to identify a 
difference between an organization’s usual customer base and an identified segment of 
the market otherwise outside of the scope of the organization’s business (Brett, 2018). 
Porter (1991) described competitive advantages as two basic types: (a) “lower cost than 
rivals” or (b) “the ability to differentiate and command a premium price that exceeds the 










Note. Porter’s Competitive Advantage Strategies. Adapted from “Competitive 
Advantage: Creating and Sustaining Superior Performance,” by M. E. Porter, 1985, p. 12. 


































Porter (2015) cautioned that organizations that are competing on the same product 
have a significant challenge because a truism of competition and strategy is that you 
cannot meet the needs of every customer. Competitive strategy is about competing to be 
unique. “If you try to meet everybody’s needs, the chances are that you won’t be very 
good at meeting anybody’s needs” (Porter, 2015). 
Strategic partnerships between a CRO and its client(s) are often the result of 
customer loyalty and service quality. Understanding market factors (budgets, timelines, 
regulations, etc.) and partnership resources and capabilities allows the formulation of 
strategy in response to industry dynamics, potentially resulting in competitive advantage 
for both the CRO and the pharmaceutical or biotech client. Lin and Darnall (2015) 
suggested that a company’s decision to form a strategic alliance or partnership was 
influenced by resource-based and institutional factors. The decision to outsource to a 
CRO and often to develop a strategic partnership is many times the result of categorizing 
the outsourced project as either an opportunity or a threat. In rationalizing between 
options, the outsourcing manager must evaluate their organization’s internal 
competencies, capital investments, technology, as well as the competencies, cost, and 
technology of the partner being considered (Lin & Darnall, 2015). Evaluation of these 
factors will identify the project as being a strategic business opportunity or a business 
threat resulting in a business partnership/alliance that is either proactive (opportunity 
driven) or reactive (threat driven) (Lin & Darnall, 2015). This process is an example of 
the RBV of strategy that focuses on the strategic partnership as a driver for competitive 
advantage (Lin & Darnall, 2015; Wang, 2014). 
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Comparative Advantage Theory 
Hunt and Morgan (1995) introduced the concept of resource advantage as a 
counter to the neoclassical theory of perfect competition. Competition involves the 
constant struggle for a comparative advantage that will yield a market position of 
competitive advantage and superior financial performance (Hunt & Morgan, 1995). This 
theory was introduced to explain how a competitive and dynamic market is preferable to 
one that is command driven. The comparative advantage theory expands on an 
organization’s tangible resources (e.g., land, labor, and capital) to include intangible 
competencies such as organizational culture, brand equity, knowledge (e.g., consumer 
and competitive intelligence), human capital (e.g., skills and knowledge of individual 
employees), and relationships (e.g., with suppliers and customers) that enable the 
achievement of superior financial performance (Hunt & Morgan, 1995). A comparative 
advantage in resources exists when an organization’s resources enable it to produce a 
product that (a)is perceived by the market to have superior value and/or (b) can be 
produced at lower costs (Hunt & Morgan, 1995). Figure 4 explains nine possible 
competitive positions of an organization relative to a competitor in terms of resource-







Competitive Position Matrix 
  Relative Resource-Produced Value 








































1 Demand is heterogeneous across industries, heterogeneous within industries, and 
dynamic 
2 Consumer information is imperfect and costly 
3 Human motivation is constrained self-interest seeking 
4 The organization’s objective is superior financial performance 
5 The organization’s information is imperfect and costly 
6 The organization’s resources are financial, physical, legal, human, organizational, 
informational, and relational 
7 Resource characteristics are heterogeneous and imperfectly mobile 
8 The role of management is to recognize, understand, create, select, implement, and 
modify strategies 
9 Competitive dynamics are disequilibrium-provoking, with innovation endogenous 
 
Note. The marketplace position of competitive advantage identified as Cell 3 results from 
the organization, relative to its competition, having a resource assortment that enables it 
to produce a product that is (a) perceived to be a superior value and/or (b) produced at 
lower costs. Adapted from “The Comparative Advantage Theory of Competition,” by S. 





Porter’s (1985) five forces model enables organizations to structurally analyze 
current industry situations. However, this model is limited in assuming a classic perfect 
market as well as static market structure (Wang, 2014). In 21st century dynamic markets, 
this model is increasingly challenging as industries have become more complex with 
inter-relationships that focus on firm-specific determinants of profitability rather than 
industry-specific ones (Rumelt, 1991; Wang, 2014). Focus on the capabilities and the 
heterogeneous resources that organizations use has become more important than solely 
based on products and market positioning as the primary source of competitive advantage 
(Rumelt, 1991; Wang, 2014). This approach further describes the RBV strategy. 
The RBV of the organization focuses on the internal environment as a driver for 
competitive advantage. Kay (2018) described a firm as a collection of capabilities that 
provide a more illuminating perspective for understanding the diversity of business 
organization over geographies and over time. Porter (1991) argued that the origins of 
competitive advantage are valuable, often intangible resources (competencies) that an 
organization has such as skills and reputation. An organization’s resources are often 
classified as skills, knowledge, and technology (Wang, 2014). A key for achieving 
competitive advantage is a business system which harmonizes the resource base, system 
of operation, and the range of products offered to achieve effective value-creation (Otola 
et al., 2013). Barney (1991) stated that an organizations resources are “all assets, 
capabilities, organizational processes, firm attributes, information, etc. controlled by a 
firm that enable the firm to conceive of and implement strategies that improve its 
37 
 
efficiency and effectiveness”. The RBV is a concept that identifies an organization’s 
resources and inherent competencies as determinants of its success (Otola et al., 2013). 
Barney (1991) indicated that resources that determine competitive advantage should be 
valuable, inimitable, rare, and non-substitutable. Otola et al. (2013) further summarized 
Barney (1991), Krupski (2011), and Bratnicki (2000) and postulated that that resources 
(core competencies) that are strategic should be 
• important and represent a strategic value to the organization; 
• rare in terms of occurrence in current and potential competitors; 
• difficult to be copied by the competitors; 
• have limited mobility; 
• ensure permanent competitive advantage; 
• non-substitutable (irreplaceable); and 
• expensive when imitated. 
In the RBV, competitive advantage is created from the efficiency of the resources that 
enable the organization to produce greater perceived benefits for the same costs or the 
same perceived benefits for a lower cost (Brahma & Chakraborty, 2011).  
Porter (1991) provided a counter-narrative and suggests that resources are not 
valuable in and of themselves but are valuable because they allow organizations to 
perform activities that create advantage in specific markets. The competitive value of 
resources can be enhanced or eliminated by competitor behavior, buyer needs, or changes 
in technology (Porter, 1991). Peteraf and Barney (2003) explained that the resource-
based view is not a substitute for industry level analytic tools such as five-forces analysis, 
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strategic group analysis, or macro environment analysis, but rather a complement to these 
tools. 
CROs and COVID-19 
During the early months of the COVID-19 pandemic beginning in early 2020, 
preclinical CROs were largely open for business. However, in some regions of the 
country (and world), the restrictions on movement due to COVID-19 caused some 
pharmaceutical and biotech companies to slow, and in many cases end, their internal 
preclinical activities (BioCentury, 2020). Although representatives of the Department of 
Homeland Security included and identified workers conducting research critical to 
COVID-19 response as essential critical infrastructure workforce, pharmaceutical and 
biotech companies held back from conducting in-house R&D discovery research in favor 
of clinical trials or critical investigational new drug-enabling (IND-enabling) studies 
(BioCentury, 2020). These companies chose to restrict/limit company access and as a 
result, most internal preclinical programs were stopped and ended. 
Only 3% of 368 global preclinical CROs indicated they had closed and suspended 
operations (BioCentury, 2020). Most (67%) were open and fully operational, and 30% 
were open but only minimally staffed and operating at partial capacity (BioCentury, 
2020). While 60% of the CRO representatives surveyed by BioCentury indicated they 
were working on non-COVID-19 projects, almost 25% had programs related to the 
outbreak (BioCentury, 2020). 
The COVID-19 pandemic will likely affect the biopharmaceutical industry by 
impacting the CRO and biopharmaceutical companies financially, by directly impacting 
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production and demand, and by creating market disruption. Continued CRO outsourcing 
during the COVID-19 pandemic may provide some pharmaceutical and biotech 
companies the opportunity to establish relationships/partnerships with a CRO that may 
lead to continued work and outsourcing in the future. As outsourcing continues, a shift in 
business priorities may occur that may place more perceived risk on the outsourced 
preclinical project not being conducted in-house but may forge a strategic partnership 
with the CRO that builds continued trust and a lasting relationship. It is likely that 
because of the pandemic, outsourcing will increase in the 2020s and beyond. The 
outcome of this outsourcing trend may result in possible structural changes in the drug 
development process. As the industry navigates a new post-pandemic normalcy in the 
coming years, further research exploring the effects of increased outsourcing and the 
partnerships and relationships required to ensure business continuity and financial 






Preclinical CROs Open During COVID-19 
 
Note. Most preclinical CROs remain open during the pandemic as pharmaceutical and 
biotech companies aim to meet their goals by outsourcing more projects. Adapted from 
“CROs Might Be the Engine That Keeps Preclinical Research Moving During COVID-
19,” by Biocentury Inc., 2020. Copyright 2020 by BioCentury Inc. 
 
Transition  
The types of partnerships that CROs are engaging in are changing. 
Pharmaceutical companies are now outsourcing entire programs and the CRO is 
becoming a permanent supplier of certain critical functions. With the recent budgetary 
pressure pharmaceutical and biotech companies are under, there has been a shift to more 
strategic outsourcing where CROs are no longer mere service providers, but full-service 
Fully Operational Partially Operational Closed
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collaborators and strategic business partners. The resulting increased outsourcing has 
caused a more focused engagement between the CRO and Pharmaceutical companies, 
and this partnership will be a synergistic collaboration that provides incentives for both 
industries. However, as a service provider, the preclinical CRO does not share equal risk 
in these strategic partnerships. The preclinical CRO has different business interests than 
their pharmaceutical/biotech company clients (Parrett, 2013) and as a result, strategic 
partnerships must be agreed to and understood with complete transparency. In Section 1, 
I provided the background of the problem, the research purpose, the research 
methodology, and a review of the scholarly and professional literature. 
In Section 2, I include the purpose and method of the study, the application and 
implication for business use, and implications for social change. In Section 2, I also 
discuss the role of the researcher and study participants, data collection and organization 
techniques, as well as describe efforts to ensure the validity and reliability of the research 
study. In Section 3, I present the findings of the research and implications for social 





Section 2: The Project 
Corporate downsizing and consolidation and economic uncertainty led the 
pharmaceutical research sector to streamline operationally, reduce costs, and improve 
efficiencies (Green, 2009). Pharmaceutical companies are now outsourcing entire 
programs and the CRO is becoming a permanent supplier of critical functions (Lin & 
Darnall, 2015; Parrett, 2013). With the budgetary pressure pharmaceutical and biotech 
companies are under, there has been a shift to more strategic outsourcing where CROs 
are no longer mere service providers, but full-service collaborators and strategic business 
partners (Getz, 2014; PAREXEL, 2013). By understanding the mutualistic interactions 
that are required for improved success, decision makers may be able to improve strategic 
collaboration between pharma and CROs, which may lead to scientific innovations in 
pharmaceutical research that will not only save lives but provide for a healthier and 
improved quality of life. The intent of this qualitative study was to explore and evaluate 
current business strategies that have focused engagement between the CRO and pharma 
to create synergistic collaborations that are financially and scientifically mutually 
beneficial. Based on known data and industry trends, I used a multiple case research 
strategy to collect and analyze qualitative data to explore empirical innovative 
approaches to strategic collaborations between a CRO and pharma/biotech. 
Purpose Statement 
The purpose of this qualitative multiple case study was to ascertain the 
perceptions and experiences of key industry decision makers regarding the risk associated 
with strategic partnerships between the CRO and pharmaceutical/biotech companies. The 
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targeted population consisted of nine key decision makers at pharmaceutical research 
companies (large and small pharma), biopharmaceutical research companies, and CROs 
in the United States, Europe, and Asia. Qualitative data were collected through interviews 
of chief executive officers (CEO), corporate presidents/vice-presidents, and/or scientific 
directors from the United States, Europe, and Asia. This population was appropriate for 
this study because these key industry decision makers provided accurate data describing 
the attitudes and experiences they have toward strategic business collaborations with each 
other, and how those collaborations have influenced the pharmaceutical research 
industry. The implications for positive social change include the potential to provide an 
efficient and collaborative drug discovery and development process that may result in 
novel lifesaving compounds receiving regulatory approval and getting to market faster 
and safer. 
Role of the Researcher 
Clark and Veale (2018) described that the role of a qualitative researcher is to 
collect and analyze data. I collected and analyzed data during this study. In qualitative 
research, the researcher’s involvement is defined as participatory and interpretive (Clark 
& Veale, 2018). Specifically, as the main source of data collection (i.e., the researcher), I 
examined and evaluated current market research and literature and built categories and 
themes to organize the information into a coherent and substantive review of the research 
topic. As the researcher, I mediated the data collection process by asking questions that 
provided insight into the outsourcing aspect of pharmaceutical research. Moreover, I 
conducted interviews with participants to evaluate how preclinical CROs view risk 
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responsibility as a service provider in strategic partnerships, knowing they have different 
business interests than their pharmaceutical/biotech company clients.  
In this study, I adhered to the protocols provided in The Belmont Report (National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research, 1979) and followed basic ethical principles of (a) respect for persons, (b) 
beneficence, and (c) justice. I applied these general principles by (a) providing a consent 
form to ensure that the participants understood and were informed of the purpose of the 
study, (b) examining whether the research was properly designed and justified on the 
basis of a favorable risk/benefit assessment for participating in the study, and (c) creating 
a fair selection process for participants. To ensure confidentiality, protect the privacy and 
identity of individuals and/or organizations, and to minimize researcher bias, 
alphanumeric identifiers were used as pseudonyms instead of participant or company 
names, as suggested by Saunders et al. (2015). Further, Sorsa et al. (2015) indicated that 
scholarly researchers need to be nonjudgmental, professional, and without any prejudice. 
I conducted 30- to 45-minute interviews by phone or through Microsoft Teams as 
the data collection method for this study with nine key decision makers in the 
pharmaceutical, biotech, and CRO industries. The target population included participants 
who were company presidents/vice presidents, CEOs, and directors. Key nonclinical 
pharmaceutical industry decision makers were interviewed to gain insight describing the 
attitudes and experiences they have toward strategic business collaborations with each 
other, what risk responsibilities service providers (i.e., CROs) assume in a 
scientific/business strategic partnership, and how those collaborations have influenced the 
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pharmaceutical research industry (see Appendix A). The in-depth, one-on-one 
semistructured interview technique allowed me to solicit direct answers from the research 
participants. The unstructured format of the interview questions allowed participants to 
provide thoughtful answers and opinions (Bernard, 2013; Moustakas, 1994). 
As a member of the preclinical research field, I interact with key decision makers 
at biotech (bio) and pharma companies and can influence their scientific programs and 
business strategy. Some of the participants were current or past business clients. 
Bracketing mitigates unacknowledged preconceptions related to the research to increase 
the objectivity of the project (Taverno Ross & Francis, 2016). The bracketing process 
built perspectives for a comprehensive summation of current pharmaceutical research 
trends in the context of outsourcing and strategic partnerships. Clark and Veale (2018) 
suggested that, during the interview process, the interviewer should avoid leading the 
participants’ responses by reacting indifferently to their answers and engaging 
conscientiously in a subjective perception of their experience. The interview questions 
were open-ended and specifically related to outsourcing and strategic partnerships. The 
interviewing process continued until data saturation was reached. Data saturation is 
reached when no new information is gained and no new coding or themes are determined 
from the interviews (Fusch & Ness, 2015). The interview process begins to replicate 
results when data saturation is reached (O’Reilly & Parker, 2013; Saunders et al., 2018). 
Evaluation and analysis of the collected information may provide an understanding of the 
mutual interactions and risks that are required for improved success between 
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pharmaceutical/biotech companies and CROs in efforts to foster business innovations that 
will not only help save lives, but also provide for a healthier and improved quality of life. 
Participants 
The target population included nine participants who were key senior level 
decision-makers in the pharmaceutical, biotech, and CRO industries (e.g., company 
presidents/vice presidents, CEOs, and directors). I used a stratified purposeful sampling 
technique to identify the key decision makers (Bryman, 2016). The participant population 
was selected from national and international pharmaceutical research companies, biotech 
companies, and CROs throughout the preclinical pharmaceutical research industry. The 
selection and solicitation of participants for this study was thoughtful, targeted, and 
nonrandom. I contacted participants for interviews directly via Microsoft Teams. 
Although a minimum of at least one participant could be studied and deemed an 
appropriate sample size in a case study (Njie & Asimiran, 2014), the pursuit of a rich data 
sample from each business segment within the preclinical research industry required 
purposive sampling from several participants from each business segment to provide the 
most in-depth information. Participants were selected from a client database made 
available to me by my employer. The participants were selected from appropriate 
business segments that represent national and international pharmaceutical research 
companies, biotech companies, and CROs, and were initially contacted via email or 
telephone using the contact information made available to me by my employer to solicit 
participation in this study. The senior level participants who were interviewed were 
assumed to have adequate experience and breadth of knowledge, based on position/title 
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(e.g., company president/vice president, CEO, and director), necessary to provide in-
depth responses to the interview questions; therefore, no additional eligibility criteria 
were required. 
To develop a positive relationship with participants, I notified each participant of 
aspects of the research that could influence their decision to participate (Marrone, 2016). 
I ensured that each participant was provided complete anonymity by using a pseudonym 
(e.g., PharmBio1, PharmBio2, CRO1, CRO2) to conceal the participant’s specific 
identity, and ensure that each participant understood and voluntarily agreed to participate 
in the research. I provided an informed consent form to each participant after receiving 
IRB approval. Drake (2013) indicated that a participant can withdraw from the study at 
any time via any form of written communication. Participants were not forced to answer 
any questions that they were uncomfortable or unwilling to answer (Rodrigues et al., 
2013). 
Research Method and Design  
Research Method 
A qualitative study design is used to explore possible shared elements and 
opinions from the independent inquiry of personal thoughts, attitudes, and perceptions of 
participants and provides an in-depth understanding of the social world by asking open-
ended questions to learn about the social circumstances, experiences, perspectives, 
behavior, knowledge, and histories of those participants (Kelly, 2016; Ritchie et al., 
2014). Whereas quantitative research is typically objective, tangible, empirical, 
deductive, and appropriate to study a topic when knowledge of the subject is already 
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known (Antwi & Hamza, 2015), a qualitative research method is used to provide insight 
into the motivations, attitudes, perceptions, experiences, and values of participants by 
allowing a subjective, open, confidential, and anonymous dialogue from individuals who 
may not otherwise share their thoughts and opinions (Kelly, 2016; Smollan, 2015). 
Quantitative and qualitative elements constitute mixed methods research and are 
appropriate for exploration that includes both types of data (Almalki, 2016; C. B. Gibson, 
2017). A qualitative research method was appropriate for this study because it was used 
to provide an in-depth understanding of the lived experiences of the participants, derived 
from first-person reports (Moustakas, 1994), to determine if strategic partnerships 
between the CRO and pharma have been mutually beneficial. Based on known data and 
industry trends, empirical innovative approaches to strategic collaborations between a 
CRO and pharma/biotech were evaluated. Using deductive reasoning, I evaluated these 
business models to determine if risk-reward collaborations can be mutually beneficial. I 
evaluated outsourcing trends and general financial information. Additionally, a 
qualitative analysis of specific CRO/pharma collaborations provided a general industry 
overview of business relationships between pharmaceutical research companies and the 
biotech industry and their outsourcing partners (i.e., CROs). 
Research Design  
I considered three research designs for a qualitative study exploring business 
strategies: (a) case study, (b) ethnography, and (c) phenomenology. Case study research 
is a strategy of inquiry whereby the researcher investigates a phenomenon to provide an 
analysis of the context and processes that define the theoretical issues being studied for a 
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group of research participants (Njie & Asimiran, 2014). Case study research is defined by 
interest in individual cases rather than the methods of inquiry used, is typically used to 
investigate and analyze a single or collective case, and is particularistic, descriptive, and 
heuristic (Hyett et al., 2014). A single case study delineates a single individual, group, 
program, or event and concentrates intrinsically on it to learn more about a poorly 
understood situation, phenomenon, or real-world experience (Freeman et al., 2015; Njie 
& Asimiran, 2014). Multicase studies (multiple case studies) include a collection of data 
from multiple individual sources such as groups and people (Sugar, 2014). Ethnography 
describes a culture’s characteristics (e.g., pharmaceutical industry) through intimate, 
often face-to-face, direct observations and interactions with subjects (e.g., interviews and 
documentary data), which are triangulated using multiple data sources, and offers a 
qualitative approach that results in detailed, inductive, interactive, recursive data 
collection and analytic strategies to build comprehensive accounts of different social 
phenomenon (Mohajan, 2018). Phenomenology describes experiences as they are lived 
from an individual perspective (Moustakas, 1994). The researcher’s aim in case analysis 
is to learn strictly from the point of view of the study participant as an immediate state in 
consciousness (Creely, 2016; Marshall & Rossman, 2016) that provides the most in-depth 
information relevant to the questions that are asked (Njie & Asimiran, 2014). 
Although an ethnographic design would have provided an in-depth description of 
the pharmaceutical industry’s culture, a more specific understanding of individual 
experiences and opinions was needed. Descriptive transcendental phenomenology would 
have allowed me to gain meaning from lived experiences, perspectives, and knowledge 
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(Kelly, 2016; Moustakas, 1994). Creely (2016) described this Husserlian sense of 
meaning as a transcendent attribute of describable consciousness, cogent for a 
phenomenological approach to investigative research. However, a phenomenological 
design is subjective and integrates the collective views of the researcher and participants 
by exploring the emotional and affective reactions experienced by those going through 
the phenomenon (Tuohy et al., 2013). This would have been beyond the scope of this 
research. 
A case study is an embodiment of details about specific subject matter that results 
in an intensive analysis of complex social phenomena that allows the researcher to retain 
holistic and meaningful characteristics of real-life events (Njie & Asimiran, 2014). The 
case study design focuses on a sample that provides the best and the most in-depth 
information, where the sample size is less important than the depth and richness covered 
by the purposive sampling of a single or a few participants necessary to arrive at 
interpretations and conclusions rich in details reflective of the case (Njie & Asimiran, 
2014). Further, a multiple case study provides basis for transferability of the same 
phenomenon in a variety of contexts that may reveal a broader trend significant on a 
wider scale (Rule & John, 2015). A case study research approach was used to draw 
conclusions from the experiences of decision makers in the pharmaceutical, biotech, and 
CRO industry regarding strategic partnerships/collaborations between CROs and 
pharma/biotech companies. I considered the multiple case study research design 
appropriate to explore business strategies focused on strategic partnerships. 
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Data saturation is reached when new data repeat what was expressed in previous 
data (Saunders et al., 2018) and when no new data have been found (Fusch & Ness, 2015; 
O’Reilly & Parker, 2013), what Sandelowski (2008) refers to as informational 
redundancy. Saunders et al. (2018) suggested a similar description of data saturation as 
the point when the researcher begins to hear similar comments repeatedly during 
interviews. Strauss and Corbin (1998) assessed saturation as a matter of degree, 
suggesting that saturation occurs when further data collection becomes counterproductive 
and does not add anything new to the data. 
Population and Sampling 
The purpose of this qualitative multiple case study was to ascertain the 
perceptions and experiences of key industry decision makers regarding the risk associated 
with strategic partnerships between the CRO and pharmaceutical/biotech companies. I 
used purposive sampling of key decision makers in the pharmaceutical, biotech, and CRO 
industries. The data were collected using the purposive sampling technique/method by 
conducting interviews with participants selected because of their personal experience or 
knowledge of the topic (as recommended by Bryman, 2016, and Cleary et al., 2014) and 
examining and evaluating current market research and literature. All of the interviews 
were conducted over the phone or via a Microsoft Teams meeting due to the national or 
international proximity of the selected key decision maker’s physical location or that of 
their company. 
Speaking with participants over the phone (or similar communication technology) 
provides inherent advantages (compared to face-to-face interviews) which include (a) 
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confidentiality, (b) mitigating bias, and (c) promoting flexibility (Morse & Coulehan, 
2015). When no new data are obtained from the study participants (saturation) and the 
information gathered becomes redundant, the interviewing process is ended as the 
required sample size has been met (Cleary et al., 2014; O’Reilly & Parker, 2013). The 
required sample size is based on the ability to reach theme saturation without new 
concepts or themes emerging (Bryman, 2016; Cleary et al., 2014; O’Reilly & Parker, 
2013). The criteria for key decision makers in this study were roles of company 
presidents/vice presidents, CEOs, and directors. Participation in the study was voluntary, 
and therefore, there was no remuneration for participation. 
The population for the study was suitable to evaluate how key industry decision 
makers regard the risk associated with strategic partnerships between the CRO and 
pharmaceutical/biotech companies. A sample size of nine key decision makers allowed 
for comprehensive and substantive data from an appropriate sample distribution of both 
national and international pharmaceutical research companies throughout the 
pharmaceutical research industry.  
In this study, I used the stratified purposeful sampling method. Emmel (2013) 
explained that qualitative sampling is an iterative set of decisions throughout the research 
process and not a single planning decision. Anney (2014) explained that qualitative 
sampling is assumed to be naturalistic and conforms to the inquiry and divergent reality 
and purpose of the study in a cohesive logic to develop idiographic knowledge. 
Purposeful sampling provides informed perspective that can enhance the quality of 
exploration synthesis (Flick, 2015). Information-rich cases (e.g., participants) provide the 
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logic and power of purposeful sampling and yield in-depth comprehension rather than 
empirical generalizations (Palinkas et al., 2015; Patton, 2015). In stratified purposeful 
sampling, maximum variation is critical in providing the widest variety of perspectives 
possible within the sampling population and between groups of participants within that 
population to allow for comparison (Koerber & McMichael, 2008; Palinkas et al., 2015; 
Patton, 2015). I, as the researcher, was reflexive and followed the iterative nature of 
qualitative research to make decisions in response to empirical findings and theoretical 
developments, as described by Emmel (2013). 
Ethical Research 
The Walden University Institutional Review Board (IRB) representatives are 
responsible for ensuring that all Walden University research complies with the 
university’s ethical standards as well as U.S. federal regulations. The IRB reviewed and 
approved this study (IRB approval number 10-30-20-0223395) to protect the rights, 
interests, and welfare of the study participants, and maintain the ethical standards of the 
university (Amdur & Bankert, 2011). The Belmont Report (National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Research, 1979) and its 
principles focus on respect for the research participants’ individual autonomy and its 
derivative application, informed consent (Tene & Polonetsky, 2016). Informed consent is 
further based on the principles of privacy and a process of communication between the 
researcher and the research participant that culminates in the authorization or refusal to 
participate in a research study (Bhattacharya et al., 2016; Grady, 2015). I notified 
participants of aspects of the research that could influence their decision to participate. I 
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ensured that each participant understood and voluntarily agreed to participate in the 
research. There were no incentives for participation in this study and withdrawal from the 
study at any time was an option. An informed consent form was provided to the 
participant pool after receiving IRB approval. A participant could have withdrawn from 
the study at any time by simply informing me via any form of communication (e.g., 
phone call, email, other form of written correspondence). The consent form included 
background information of the study and described the voluntary nature of the study. 
The interpersonal capacity to respect each participant should be a primary aim of 
the qualitative researcher as it demonstrates esteem for the participants (O’Grady, 2016). 
Specifically, protecting the privacy and confidentiality of the study participants was an 
important aspect of this research. To ensure confidentiality and protect the identity of 
individuals and/or organizations, and to minimize researcher bias, alpha numeric 
identifiers (pseudonyms) were used instead of participant or company names (Saunders et 
al., 2015). All research data including interviews and any study related documents will be 
secured and maintained for 5 years following completion of the study and will then be 
destroyed. 
Data Collection Instruments 
The primary data collection instruments for this study was a qualitative research 
interview with each participant and the collection and evaluation of current public 
company documents, market research, and/or literature. Since real-world phenomena 
cannot be measured by external instruments, Yin (2016) explained that the qualitative 
study researcher serves as the principal research instrument to make inferences about 
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lived experiences by interviewing the research participants. The in-depth, one-on-one 
semistructured interview technique allowed me to solicit answers from the research 
participants to approximately 10 questions. The semistructured format of the interview 
questions allowed participants to provide thoughtful answers and opinions (Bernard, 
2013; Moustakas, 1994). The interview was a social interaction where the validity of the 
data was the result of cooperation between the researcher and the study participant and 
appropriate congruency with the purpose of the research as explained by Castillo-
Montoya (2016). I used observation, documentation, and evaluation/interpretation of each 
participant’s interview question answers to ensure the reliability, validity, and accuracy in 
the study as described by Yilmaz (2013). Each study participant was asked the same 
interview questions to ensure consistency. I used an interview protocol (see Appendix A) 
that set the overall tone and parameters for the interviews. By implementing an interview 
protocol, the reliability of the study was further solidified (Yin, 2014). During and after 
the approximate 30-45- minute interviews, I used a reflective journal to make comments 
that may further clarify any issues/observations made during the discussions as suggested 
by Muswazi and Nhamo (2013). 
To ensure that the data collected from participants’ interviews was reliable and 
valid, I used member checking to validate that the collected information was accurate. 
Member checking is a process where the researcher shares a concise summary of the 
collected data with the participant allowing the participant the opportunity to review and 
provide clarifications and/or confirmation that the information is accurate (Bekhet & 
Zauszniewski, 2012; Harper & Cole, 2012). 
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Data Collection Technique 
Using a semistructured interview technique, outsourcing trends were evaluated, 
business collaborations and partnerships were identified, and supporting information was 
collected and analyzed to explore and evaluate current business strategies that have 
focused engagement between the CRO and pharma to create collaborations that are 
financially and scientifically mutually beneficial. The primary instrument that was used 
for data collection was a qualitative research interview method (Marshall & Rossman, 
2016) and extensive review of current public company documents, market research, 
and/or literature. Using multiple data sources and data collection procedures enhance the 
information gathered (Robinson, 2013) and result in further credibility and 
trustworthiness through the data triangulation process (Carter et al., 2014; Yin, 2014). 
The interviews provided a timely and accurate description of the current attitudes 
that key decision makers have toward strategic business collaborations with each other, 
and how those collaborations have influenced the pharmaceutical research industry. The 
information was collected during Microsoft Teams meeting interviews to obtain opinions, 
business strategy and theory, and current views/perceptions. As the principal instrument 
in this qualitative multiple case study, I asked specific open ended questions (see 
Appendix B) during the interview (Freeman et al., 2015) to (a) elicit information from the 
participants, (b) understand the underlying basis for that information, and (c) adequately 
appreciate participants’ perceptions (O’Reilly & Parker, 2013). The interviews were 
recorded and were then transcribed electronically into text documents using voice 
recognition software. Face-to-face interviews (when possible) may have allowed me to 
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capture verbal and nonverbal data, behaviors, and/or emotions (Speer & Stokoe, 2014), 
but may have also resulted in a smaller sample size (participant pool) and potentially 
rushed responses because of the predetermined interview time (duration set by protocol). 
To mitigate potential disadvantages of the interview process, participants were 
offered the option to participate in a Microsoft Teams meeting interview (video 
conference) or simply participate via audio in a Microsoft Teams meeting without the 
video capture option. These processes allowed for an environment that can promote 
privacy, confidentiality, and the level of comfort/ease most appropriate for each 
individual participant. Microsoft Teams meeting interviews were recorded using the 
software-recording feature to ensure the accuracy of the participants’ responses. I 
continued the interviewing process until data saturation had been reached and no new 
data was discovered, as explained and suggested by O’Reilly & Parker (2013), Palinkas 
et al., (2015); and Sandelowski (2008). 
The member checking process involved reviewing, interpreting, and summarizing 
the interview recordings. As suggested by Bekhet and Zauszniewski (2012) and Harper 
and Cole (2012), I shared a concise summary of the collected data with each participant 
allowing the participant the opportunity to review and provide clarifications and/or 
confirmation that the synthesis of their information was accurate and appropriately 
represented the content and intent of their responses. Based on follow-up conversations 
with each participant, the summary responses were updated as necessary, therefore 
confirming the data, and enhancing the dependability and credibility of the research. 
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Data Organization Technique 
W. Gibson et al. (2014) suggested the use of software to keep track of and 
organize data. For this study I created and maintained password-protected electronic data 
logs through Microsoft Word and Excel that were used to categorize the data. These 
software programs allowed me to code and identify data themes to appropriately 
categorize and organize the collected data as suggested by Fusch & Ness (2015) and 
Patterson et al. (2014). The electronic data will be stored on a password-protected 
universal serial bus (USB) flash drive and computer for 5 years, after which all data will 
be deleted and/or destroyed. 
I used a reflective journal to document information about the study. The journal 
allowed me to go through a reflective process and critical thinking with the ability to self-
monitor, be self-directive and autonomous, while allowing for the development of new 
perspectives and potential outcomes as described and suggested by Constantinou and 
Kuys (2013) and Peredaryenko and Krauss (2013). The journal also allowed me to use 
bracketing to examine preconceived assumptions and/or ideas I may have had about the 
phenomenon, as described by Chan et al. (2013). 
Data Analysis 
Yin (2014) described a five-step process for data analysis when conducting a case 
study: (a) compile data, (b) disassemble the data, (c) reassemble the data, (d) interpret the 
data, and (e) draw conclusions from the data. Key themes and opinions should emerge 
from the data analysis process that should inform the research question. The overarching 
research question for this study is: What strategies do service providers (i.e., Contract 
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Research Organizations) and pharmaceutical/biotech companies use to develop strategic 
partnerships during the drug discovery and development process? Using the open-ended 
interview questions should allow responses to be grouped into overarching themes (Irvine 
et al., 2013). Descriptive analysis was performed, and any response bias was determined. 
Data triangulation is used by researchers to ensure appropriate objectivity by 
referencing multiple sources (Denzin, 2012; Patton, 2015; Yin, 2014). Methodological 
triangulation was used in this study and involved utilization of data from different 
sources including detailed responses from interview questions and data from various 
respective company and industry documents. I collected data via interviews, evaluation 
of current public company documents, market research, and/or literature. Further, using 
Yin’s five step process (described previously) I identified themes, codes, categories, and 
descriptions to analyze the data appropriately and efficaciously (Campbell et al., 2013; 
Yin, 2014). Through this data analysis, I gained an understanding of specific themes, 
patterns, and relationships associated with key words from the participant interviews. I 
used these data to evaluate the relationship between the emerging themes and the 
conceptual framework as described/suggested by Klag and Langley (2013). I compared 
and analyzed responses from the interview process, available company documents, 
current market research, and/or literature in order to substantiate the research study, the 
collected data, conclusions, and outcomes. By reviewing emerging concepts in the 
literature and identifying possible relationships to the identified themes, I analyzed how 




The collected data was organized using an electronic filing system based upon the 
apha-numeric identifiers assigned to each participant. NVivo (Release 1.4) software was 
used to code and identify themes for the transcribed interview data. By using NVivo 
software, accuracy and consistency was assured throughout the data analysis process 
(Corbin & Strauss, 2015). 
Reliability and Validity 
Reliability and validity strategies ensure that the research study results are 
trustworthy, accurate, replicable, appropriate, and well-founded (Barnham, 2015; Leung, 
2015; Tracy, 2013). The quality of the qualitative research is evaluated based on the 
credibility (internal validity), transferability (external validity), dependability (reliability), 
and conformability (objectivity) of the data (Leung, 2015; Morse, 2015). Reliability and 
validity are intended to make qualitative research rigorous; and therefore, trustworthy 
(Morse, 2015; Reinecke et al., 2016). 
Reliability 
Reliability in qualitative research addresses the extent that the results of the study 
can be replicated and the consistency of the investigator’s research approach throughout 
the investigation (Marshall & Rossman, 2016). Reliability in qualitative studies includes 
the dependability, consistency, and repeatability of the data collection, interpretation, and 
analysis (Morse, 2015; Zohrabi, 2013). Reliability of the interview process was achieved 
through stratified purposive sampling. To be more specific with the term of reliability in 
qualitative research, Lincoln and Guba (1985) use dependability in qualitative research, 
which closely corresponds to the notion of reliability in quantitative research. 
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Dependability of the data collection was ensured by using the modified van Kaam 
method for data analysis (Moustakas, 1994). Dependability describes when researchers 
replicate previous research by using similar resources in a similar context or background 
(Venkatesh et al., 2013). The interview protocol also contributed to the rigor of the study 
and further demonstrated dependability. Dependability uses an audit trail concept to 
establish the trustworthiness of the research findings (Jones, 2014) and stability of those 
findings over time (Anney, 2014). I employed the strategies noted above to ensure the 
reliability of the study research. 
Validity 
In qualitative research, credibility describes the accuracy of the collected data to 
reflect the observed social phenomena (Morse, 2015) and the confidence and 
believability of that data (Anney, 2014). Data credibility was ensured by the interview 
participants using member-checking of their interview responses. Participants were 
allowed to review and provide clarifications and/or confirmation that the synthesis of 
their information was accurate and appropriately represented the content and intent of 
their responses (Bekhet & Zauszniewski, 2012; Harper & Cole, 2012). The member-
checking process confirmed the accuracy and completeness of the interview question 
answers (Lub, 2015; Morse, 2015; Wilson et al., 2014), and enhanced credibility and 
ensured trustworthiness (Beck, 2014). Confirmation of credibility included 
methodological triangulation involving the use of multiple data collection methods as 
described by Heale and Forbes (2013) and included (a) a research interview method using 
open-ended questions, (b) an extensive evaluation of current public company documents 
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and/or market research, and a peer-reviewed literature review, and (c) data analysis and 
characterization through coding. Transferability (external validity; generalizability) 
describes the applicability of the data to another context or individuals (Leung, 2015; 
Morse, 2015; Sousa, 2014). The extent to which others can confirm the study findings to 
ensure the data reflect the opinions and experiences of study participants rather than those 
of the researcher (as parallel to objectivity) is confirmability (Abdalla et al., 2018). 
Hussein (2009) suggested that confirmability and transferability are enhanced by using 
methodological triangulation and utilization of data from different sources. The use of 
comprehensive, detailed, and consistent processes to collect information (e.g., using 
interview questions) and confirm the credibility of the data using peer-reviewed sources, 
current market research, and public company information (i.e., triangulation), will 
provide the future researcher the ability to repeat/replicate the study results or apply the 
study conclusion(s) (Beck, 2014; Heale & Forbes, 2013; Yin, 2014). Confirmability is 
linked to dependability and objectivity and is increased by data triangulation (Yin, 2014). 
Confirmability ensures that the researcher builds on the audit trail using clear and concise 
journal notes to interpret the study data based on the research findings and not personal 
biases (Rapport et al., 2015; Zitomer & Goodwin, 2014). Data saturation for this study 
was reached when there was enough information to replicate the research (described by 
Saunders et al., 2018) and when the point of no new data had been reached (described by 
Fusch & Ness, 2015; O’Reilly & Parker, 2013). A main objective of qualitative research 
is to provide valid and reliable factors that support the study design and reduce researcher 
bias or false interpretations (Bernard, 2013). The study design ensured data validity 
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through a controlled, intentional interview process (with informed consent), and by using 
logical and observable steps to ensure credibility (e.g., member-checking and 
methodological triangulation) and trustworthiness of study results as explained by Tracy 
(2013). Bekhet and Zauszniewski (2012) and Denzin (2012) suggest that triangulation be 
used to review, compare, and contrast multiple data sources to establish credibility of the 
study data and results. I employed the strategies noted above to ensure the validity of the 
study research. 
Transition and Summary 
In Section 2, I provided a detailed review of the research methodology, identified 
the study population and participants, and defined the role of the researcher. Ethical 
research practices were discussed, and data collection/organization and analysis 
techniques were identified. Efforts to ensure the validity and reliability of the research 
study were also described. In Section 3, I include a complete report and description of the 
study results and evaluation/analysis of the study data. A summary of study findings is 
presented and a discussion of the study results, along with study conclusions are 
presented. Areas for future research were identified at the conclusion of Section 3. 
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Section 3: Application to Professional Practice and Implications for Change 
The purpose of this qualitative multiple case study was to explore strategies to 
develop partnerships between the CRO and pharmaceutical/biotech companies and risk-
sharing collaborations that aim to provide financial and scientific value and benefits. The 
data were obtained from published current market research, and from interviews 
conducted with key senior level decision makers in the pharmaceutical, biotech, and CRO 
industries selected from national and international companies throughout the preclinical 
pharmaceutical research industry. The research findings provide an understanding of the 
mutual interactions and risks that are required for improved success between 
pharmaceutical/biotech companies and CROs to foster business innovations and strategic 
collaborations that will not only help save lives but also provide for a healthier and 
improved quality of life. 
Presentation of the Findings 
The goal of this study was to answer the research question: What strategies do 
service providers (i.e., s) and pharmaceutical/biotech companies use to develop strategic 
partnerships during the drug discovery and development process? To gain an in-depth 
understanding of the business strategies and collaborative processes used in developing 
and/or sustaining a partnership, I interviewed nine key senior level decision makers in the 
pharmaceutical, biotech, and CRO industries (i.e., company presidents/vice presidents, 
CEOs, and directors). These participants were assumed to have adequate experience and 
breadth of knowledge, based on position/title, necessary to provide in-depth responses to 
the interview questions. 
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Yin (2014) described a five-step process for data analysis when conducting a case 
study: (a) compile data, (b) disassemble the data, (c) reassemble the data, (d) interpret the 
data, and (e) draw conclusions from the data. This data analysis process resulted in key 
themes and opinions that informed the research question for this study. By using open-
ended interview questions, I was able to group the responses into overarching themes as 
suggested by Irvine et al. (2013). 
Denzin (2012), Patton (2015), and Yin (2014) suggested that researchers 
reference multiple sources (i.e., data triangulation) to ensure appropriate objectivity. 
Methodological triangulation was used in this study and involved utilization of data from 
different sources including the detailed responses from the interview questions and data 
from current published market research, and/or literature. Through this data analysis, I 
gained an understanding of specific themes, patterns, and relationships associated with 
key words from the participant interviews. Using semistructured interview questions, I 
evaluated outsourcing trends and identified the concepts behind business collaborations 
and partnerships to explore and evaluate current business strategies that have focused 
engagement between the CRO and pharmaceutical/biotech to create financially and 
scientifically mutually beneficial collaborations. I continued the interviewing process 
until data saturation had been reached and no new data were discovered. 
NVivo software was used to transcribe the recorded interviews. I ensured data 
credibility through member-checking, that is, by having the interview participants check 
their interview responses (i.e., transcripts). Participants reviewed and provided 
clarifications and/or confirmation that the synthesis of their transcribed information 
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accurately and appropriately represented the content and intent of their interview 
responses. I then used NVivo to code and identify themes from the transcribed interview 
data. 
I used these data to evaluate the relationship between the emerging themes and 
the conceptual framework as described/suggested by Klag and Langley (2013). I 
compared and analyzed responses from the interview process, current published market 
research, and/or literature in order to substantiate the research study, the collected data, 
conclusions, and outcomes as recommended by Anney (2014) and Heale and Forbes 
(2013). Descriptive analysis was performed by reviewing emerging concepts in the 
literature and using Yin’s five-step process to analyze how they were linked to the 
conceptual framework and how they related to competitive advantage and a strategic 
partnership. 
Once the data were coded and patterns and relationships associated with key 
words from the participant interviews were identified, key categories emerged identifying 
relationships and themes. Analyzing the data further, I established three overarching 
themes: (a) defining a strategic/essential partnership, (b) understanding the benefit of 
building a relationship, and (c) the study director is an essential asset. These themes were 
used to answer the research question. 
Analysis of the coded data resulted in specific words and key phrases that 
suggested a relationship between emerging concepts and ideas, and how they potentially 
were linked to the conceptual framework of the study and strategic partnerships. The 
incidence of key words/phrases that described factors that affect or influence an existing 
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or potential strategic partnership were tabulated and used to identify key thematic 
responses from each individual participants’ interview and collectively across all 
participant interviews (see below). 
Table 3 
 
Overarching Themes – Participant Interviews 





Understanding the benefit of 
building a relationship 
The study director is an 
essential asset 
CRO1 6 4 0 
CRO2 1 6 4 
CRO3 5 3 1 
CRO4 9 1 3 
CRO5 8 2 0 
PharmBio1 1 4 2 
PharmBio2 1 0 6 
PharmBio3 3 5 2 
PharmBio4 5 1 11 
Total Responsesa 39 26 29 
Meanb 4.3 2.9 3.2 
Total (%)c 41.5 27.7 30.8 
a Incidence specific thematic response was recorded (sum of all individual participant 
interviews). 
b Average of the incidence for specific theme response across all participants. 
c Percentage of specific theme total response across all themes (i.e., sum of total 
responses, all themes). 
 
Analysis of the participant interviews and the resulting key categories of specific 
words and phrases identified three overarching themes. For Theme 1, there were 39 
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responses by the nine participants that included the term partnership(s). This represents 
an average of 4.3 responses per study participant and a total of 41.5% of all responses by 
all study participants across all key themes. For Theme 2, there were 26 responses by 
eight participants that included the term relationship(s). This represents an average of 2.9 
responses per study participant (nine total study participants) and a total of 27.7% of all 
responses by all study participants across all key themes. For Theme 3, there were 29 
responses by seven participants that included the terms study director(s). This represents 
an average of 3.2 responses per study participant (nine total study participants) and a total 
of 30.8% of all responses by all study participants across all key themes. 
Theme 1: Defining a Strategic/Essential Partnership 
The move toward strategic partnerships continued to be a sustainable trend with 
preferred strategic partnerships in place for 82% of respondents in market survey data 
collected by Credit Suisse representatives (2018). These innovative outsourcing 
opportunities provide for collaborative partnerships that create potential efficiencies for 
R&D activities within the drug discovery and development process and improved 
profitability for the outsourced partner (i.e., CRO). 
The word partnership(s) was used a total of 39 times across all nine study 
participants, which represents an average response of 4.3 times per participant for this 
specific theme and 41.5% of total responses across the three overarching themes (see 
Table 4). The key word partnership(s) was used 269 times across all nine study 






Incidence of Individual Participant Response to Theme 1 and Key Words 





Partnership Partner Strategic Transaction(al)d 
CRO1 6 8 1 2 1 
CRO2 1 1 3 3 0 
CRO3 5 26 10 2 4 
CRO4 9 12 4 10 0 
CRO5 8 16 0 12 4 
PharmBio1 1 5 3 5 2 
PharmBio2 1 2 7 2 2 
PharmBio3 3 5 4 5 8 
PharmBio4 5 15 5 5 0 
Total 
responsesa 
39 90 37 46 21 
Meanb 4.3 10 4.1 5.1 2.3 
Total (%)c 41.5 NA NA NA NA 
Note. NA = Not applicable. 
a Incidence specific thematic response/key phrase was recorded (sum from all individual 
participant interviews). 
b Average of the incidence for specific theme/key phrase response across all participants. 
c Percentage of specific theme total response across all themes (i.e., sum of total 
responses, all themes). 





In defining what a partnership is between a pharmaceutical company/biotech 
company and a CRO, and the role that the CRO has in that partnership during the drug 
discovery and/or development process, study participants were generally in agreement 
with a few slight distinctions. Study Participant CRO5 described a strategic partnership 
as “providing some sort of value above and beyond the transactional relationship that 
occurs in the industry in general.” Additionally, participant CRO5 stated the following: 
From our perspective, a strategic partnership, and we don't typically use this 
terminology, preferred partners, strategic partnership, really what it is, is that it's 
just a relationship, just developed [sic] a relationship to the point to where when 
you end up with a hurdle, be it price, regulatory, timing, et cetera, that you can 
work together with that individual to focus on the solution and not the problem. 
It's really purely a relationship. 
Study Participant PharmBio3 explained a strategic partnership by stating the following: 
I think large companies are looking for any way that they can leverage that, 
whether it's continuing to be transactional or whether it's trying to build more 
strategic partnerships, outsourcing operations, it's generally financially good for a 
pharma company. Most of the time, CROs can do things cheaper, quicker, better 
than pharma companies can internally, because that's what CROs do. It's in their 
wheelhouse. I mean, that's the core competency, whereas pharma companies do a 
lot of other stuff. 
Study Participant PharmBio4 described a strategic partnership in terms of capacity 
constraints and indicated, “And so that's a piece of the equation for the strategic 
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partnership, is to take advantage of the facilities that are built [i.e., existing CROs] to take 
on big studies with lots of animals.”  
The phrase strategic partnership was used a total of 19 times by seven of the nine 
study participants. Fourteen of the 19 references (73.7%) were made by three participants 
representing the CRO industry and the remaining five references (26.3%) were made by 
the four participants representing the pharmaceutical/biotech industry. This suggests that 
the CRO participants overwhelmingly consider the concept of partnerships to be 
strategic. The word transaction or transactional was used a total of 21 times by six of the 
nine study participants to describe a business process/collaboration between the CRO and 
a pharmaceutical company/biotech company. Nine of the 21 references (42.9%) were 
made by three participants representing the CRO industry and the remaining 12 
references (57.1%) were made by three participants representing the 
pharmaceutical/biotech industry. Only one CRO participant and one 
pharmaceutical/biotech participant (two of nine total participants) described a partnership 
as generally transactional in nature. Similarly, one CRO participant and one 
pharmaceutical/biotech participant (two of nine total participants) considered a 
partnership as not transactional. The remaining two participants, one CRO participant and 
one pharmaceutical/biotech participant, described a partnership as likely transactional 
early in process, but evolving beyond transactional with time. Study Participant CRO3 
explained the following: 
Ideally, in a partnership, we should evolve. We should evolve into a relationship 
that goes beyond simply just transactional. However, I do think that a lot of 
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innovators still treat that partnership as a simple transaction, and I don't know that 
that partnership is still depending on the client. I think different sponsors are more 
or less comfortable in their control and oversight over that product or project. I 
think there are different levels of, basically, trust that exists in that paradigm. But 
in what I would say is certainly a more elegant, a more sophisticated measure of 
partnership, one that if you kind of, and we've all seen scenarios that are most 
slow, show slopes of that evolution of a partnering relationship [sic]. I think a true 
partnership is where you are part of each other's team. A CRO would simply be 
an extension of that sponsor’s team. They would be treated with respect. They 
would be treated with accountability. They would be expected to not only do a 
job, but to help innovate, to help create value. Not simply a pair of hands, but 
really helping to contribute intellectual property that helps not only the CRO be 
successful, but certainly helps the sponsor to be successful. 
Study Participant PharmBio1 further explained, “The sponsor [i.e., 
pharmaceutical/biotech client] doesn't just treat it as buying a product, right? It's actually, 
it's not transactional, it's a relationship. So that to me is the overall theme of all this stuff. 
And that's what I look for.” 
The general sentiment that a partnership, or perceived partnership, is an evolution 
from a typical transactional process to an established relationship with the client, supports 
a similar evolution from a market-based view of competitive strategy to a resource-based 
view of comparative advantage. Comparative advantage expands on an organization’s 
tangible resources to include intangible competencies such as organizational culture, 
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brand equity, knowledge (e.g., consumer and competitive intelligence), human capital 
(e.g., skills and knowledge of individual employees), and relationships (e.g., with 
suppliers and customers) that enable the achievement of superior financial performance 
(Hunt & Morgan, 1995). The evolution of a partnership into the intangible competency of 
a client relationship may likely define future business strategy for the industry. It is this 
resource (i.e., the partnering client relationship) that has the potential of becoming a 
comparative advantage for an organization resulting in a resource-produced superior 
value relative to what the competition can offer. Rahman et al. (2019) described an 
intangible resource as one that allows an organization to attain and sustain competitive 
advantage. The evolved client relationship becomes a valuable and inimitable resource 
that is used to gain an edge over competition. 
Theme 2: Understanding the Benefit of Building a Relationship 
The suggested evolution of a partnership to a more focused relationship is a trend 
that has occurred or is occurring in the industry. Miller (2013) explained that strategic 
relationships were part of rethinking of the traditional R&D paradigm at global 
pharmaceutical/biotech companies and this forward strategic thinking focused on the 
CRO assuming more responsibility. Typically, the CRO has been a service provider 
delivering single or multiple tasks on a per-project basis (PAREXEL, 2013). Getz (2014) 
described that this relationship has evolved to one of a strategic partnership where the 
CRO provides single or multifunctional support for entire programs reaching various 
portions of a pharmaceutical/biotech company portfolio. 
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The word relationship(s) was used a total of 26 times in the context of an 
overarching theme across eight study participants, which represents an average response 
of 2.9 times per total participants for this specific theme and 27.7% of total responses 
across the 3 overarching themes (see Table 5).  The specific key word relationship(s) was 
used 94 times across all nine study participants and was most used by participants CRO3 
and PharmBio1 (mentioned 15 times each). Fifty-seven of the 94 references (60.6%) 
were made by the five participants representing the CRO industry and the remaining 37 







Incidence of Individual Participant Response to Theme 2 and Key Words 
 Theme 2 Key words 
Participant 
Understanding the 
benefit of building a 
relationship 
Relationship(s) Risk Trust 
CRO1 4 11 7 1 
CRO2 6 14 6 1 
CRO3 3 15 20 4 
CRO4 1 4 9 6 
CRO5 2 13 5 0 
PharmBio1 4 15 16 6 
PharmBio2 0 6 7 7 
PharmBio3 5 13 3 0 
PharmBio4 1 3 7 4 
Total responsesa 26 94 80 29 
Meanb 2.9 10.4 8.9 3.2 
Total (%)c 27.7 NA NA NA 
Note. NA = Not applicable. 
a Incidence specific thematic response/key phrase was recorded (sum from all individual 
participant interviews). 
b Average of the incidence for specific theme/key phrase response across all participants. 
c Percentage of specific theme total response across all themes (i.e., sum of total 




In describing a relationship between a pharmaceutical company/biotech company 
and a CRO, and the role that the CRO has in that relationship during the drug discovery 
and/or development process, most study participants used the terms partnership and 
relationship interchangeably. Upon further inquiry, specific participant responses were 
noted that support the evolution to the relationship paradigm. Study Participant CRO2 
indicated the following:  
I've really never been part of what I would say was a true partnership. Every CRO 
uses that word and even clients will sometimes use words like “we're looking for 
a partner.” You're looking for a provider that you will have a good relationship 
with. I think this is somewhat different than being a partner. 
Participant CRO2 also stated, “I think the term [partnership] is overplayed by both 
industry and pharma and CRO. It's a close, very close working relationship…” Study 
Participant CRO3 previously described the evolution of the partnership to a relationship 
and added the following: 
Ultimately, that relationship is founded in the shared vision and mission of really 
having a benefit on all of our mutual customer [sic], which is the patient who 
desperately, desperately deserves for a world class partnership. Because I think 
that the better we can truly partner, we will deliver a higher quality product to the 
patient and we will deliver it faster. And that will take time off of an already long 
drug development cycle, which saves lives. 
Many of the participant responses that described a relationship alluded to trust or 
establishing trust. The word trust was used 29 times by seven of the nine study 
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participants. Twelve of the 29 references (41.4%) were made by four participants 
representing the CRO industry and the remaining 17 references (58.6%) were made by 
three participants representing the pharmaceutical/biotech industry. Study Participant 
CRO4 indicated the following: 
I think that is first and foremost, most important when people are talking about 
being strategic partners. Because I do think to the point of partnerships, we're 
talking about it being a give and take, and you have to trust that your partner is 
giving and taking as much as you are and doing absolutely what's best in the name 
of accuracy and speed to drug development. 
When asked what differentiates the preclinical CROs that they are doing business with 
(i.e., strategic partnerships/relationships), participant PharmBio1 stated the following: 
I think the differences lie in the trust and the personal relationships that are built. 
Honestly. I think most CROs are highly capable of doing the work. They all can 
do it. Many have been around for a long time and some have, of course, acquired 
others that have been around a long time. And so the subject matter experts, the 
experienced study directors and study teams are there at all times. So they can all 
do that. It's the communication, the support that you get. 
Study Participant PharmBio1 further summarized/reflected on the interview by saying the 
following: 
I think the overall theme for me is to have and build a relationship with the study 
team and the SME [subject matter expert] at a CRO. Providing that comfort and 
trust that I know the study is getting executed. I like to say things are going to 
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happen…Something's going to happen [sic]. But you trust that the study team is 
experienced. They know how to respond to it. They communicate all those sorts 
of things. 
When asked to describe a strategic partnership with a CRO, Study Participant CRO3 
explained the relationship as follows: 
The heart of the question is that, partnership means, if you asked one hundred 
different sponsors or even one hundred different innovators, that might mean 
something different to each of them, because it's a personal question. So in my 
mind, a partnership should be more than just a transactional relationship. And the 
optics of, “oh, you're important to us” and it's kind of fake and somewhat 
superficial [sic]. So in my ideology, my theology, a partnership is at the most 
simple level, it's where I think there is a higher level of intimacy. There's a higher 
level of trust, a higher level of just vulnerability where we're more willing to 
share, to act, all the action words that my brain is thinking of. And also the 
sponsor is as well. I mean, we're just more forthcoming. We're more vulnerable. 
This concept of a built upon and evolved relationship with a seeded establishment 
of trust between the CRO and the pharmaceutical/biotech client further supports a 
resource-based view of the organization that focuses on the internal environment as a 
driver for competitive advantage. Porter (1991) argued that the origins of competitive 
advantage are valuable, often intangible resources (i.e., competencies) that an 
organization has such as skills and reputation. As previously defined, the comparative 
advantage theory expands on an organization’s tangible resources to include intangible 
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competencies such as organizational culture, brand equity, knowledge (e.g., consumer 
and competitive intelligence), human capital (e.g., skills and knowledge of individual 
employees), and relationships (e.g., with suppliers and customers) that enable the 
achievement of superior financial performance (Hunt & Morgan, 1995). By 
understanding the benefit of building a client relationship, an organization can focus on 
the intangible resources necessary to create a lasting competitive advantage. Rahman et 
al. (2019) described this type of resource as valuable and nonsubstitutable. 
An established relationship built on trust still presented a level of risk associated 
with aspects of a project outside the direct control of the pharmaceutical/biotech company 
(e.g., regulatory requirements). The relationship also allowed for a level of internal risk 
mitigation for these regulatory concerns through the outsourcing process. The word risk 
was used a total of 80 times by all nine study participants. Forty-seven of the 80 
references (58.8%) were made by the five participants representing the CRO industry and 
the remaining 33 references (41.2%) were made by the four participants representing the 
pharmaceutical/biotech industry. Study Participant PharmBio2 stated the following: 
From my perspective as a sponsor [i.e., pharmaceutical/biotech company] and 
having worked at a CRO, I think that the sponsor in the current environment has 
one hundred percent of the risk in that relationship [partnership] and because of 
that, the individual study director and the relationships that I have with that person 
are paramount and my trust of that person and the level of expertise. 
Describing risk and risk mitigation, Study Participant CRO3 indicated the following: 
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Pharmaceutical companies have elected to outsource some aspects of their work 
to partners, contract research organizations…the reasons for that desire to 
outsource could vary based on capacity. It could vary based on speed, on value. It 
could even be a motivation based on minimizing the pharmaceutical companies’ 
internal risk and kind of putting that a little bet on the shoulders of a partner. 
Study Participant CRO3 further explained: 
Small mid-tier biotechs, most of these facilities, many don't even have a lab. So 
partnering with a contract organization isn't an option. It's a requirement. But even 
organizations that do [have an on-site lab], they may elect to outsource work 
based on, again, on the capacity of their resources internally, their expertise 
within that area. And many cases, though, I think what has driven a lot of 
outsourcing is the fact that, frankly, suppliers can often do that, work more cost 
effectively and in many instances more expeditiously than many of the sponsors 
can do themselves…But then I also commented on risk. And some of this is just 
regulatory risk, you know, particularly in a highly regulated, non-clinical 
environment, I think outsourcing work to a supplier like, you know, a large 
contract research organization or any size organization is also a way of potentially 
mitigating some internal business risk. 
This intangible competency, that being the relationship with the skills and knowledge of 
the study director (i.e., human capital), may be key for achieving competitive advantage 
and effective value-creation. 
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Theme 3: The Study Director is an Essential Asset 
Strategic partnerships between a CRO and its client(s) are often the result of 
customer loyalty and service quality. Lin and Darnall (2015) suggested that a company’s 
decision to form a strategic alliance or partnership was influenced by resource-based and 
institutional factors. Focus on the capabilities and the heterogeneous resources that 
organizations use has become more important than solely based on products and market 
positioning as the primary source of competitive advantage (Rumelt, 1991; Wang, 2014). 
The RBV is a concept that identifies an organization’s resources and inherent 
competencies as determinants of its success (Otola et al., 2013). Barney (1991) indicated 
that resources that determine competitive advantage should be valuable, inimitable, rare, 
and non-substitutable. Rahman et al. (2019) explained that these resources can be divided 
into two performance categories: resources that allow organizations to attain competitive 
advantage and others which enable organizations to sustain competitive advantage. In 
evaluating the data collected from the participant interviews conducted for this study, an 
interesting and unexpected theme emerged from the participant responses; that of the role 
and significance of the study director. The study director resource can function to attain 
competitive advantage by providing valuable and rare attributes for an organization. The 
study director can also provide inimitable and nonsubstitutable attributes that help an 
organization sustain competitive advantage. Rahman et al. (2019) classified these 
resource attributes into two categories: ex ante limits to competition (i.e., valuable and 




The study director role is defined by the Code of Federal Regulations Title 21, 
Volume 1, Part 58, Subpart B, section 58.33 (2020) which states the following: 
For each nonclinical laboratory study, a scientist or other professional of 
appropriate education, training, and experience, or combination thereof, shall be 
identified as the study director. The study director has overall responsibility for 
the technical conduct of the study, as well as for the interpretation, analysis, 
documentation and reporting of results, and represents the single point of control. 
Although the legal significance is well understood in the industry, the intangible value of 
this human capital competency and the relationships developed by and with the study 
director may not be completely appreciated in terms of a comparative business advantage 
and competitive value. 
The phrase study director was used 29 times in the context of an overarching 
theme across seven of the nine study participants, which represents an average response 
of 3.2 times per participant for this specific theme and 30.8% of total responses across the 
three overarching themes (see Table 3). Eight of the 29 references (27.6%) were made by 
three participants representing the CRO industry and the remaining 21 references (72.4%) 
were made by the four participants representing the pharmaceutical/biotech industry. This 
suggests that the pharmaceutical/biotech participants overwhelmingly considered the role 
of the study director to be noteworthy in their responses. Descriptive words such as 
experienced, good, individual, quality, and specific were used to qualify the role. 
Additionally, the study director was discussed in terms of the relationship and trust factor 
described in the previous section.  Study Participant PharmBio1 indicated the following: 
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I mean, personally, what I'd like to see, where I see the value is, and the bonus for 
me is if possible, I have the same study team or reasonably consistent study team 
across all the studies. I have the same study director, the same pathologist 
potentially working on the slides. So people have seen this and are familiar with 
the program. They're familiar with me, with my company, et cetera. And I think 
that increases the trust in the relationship. So I think there's the benefit there. 
When asked what differentiates the preclinical CROs that they are doing business with 
(i.e., strategic partnerships/relationships), participant PharmBio1 previously stated the 
following: 
I think the differences lie in the trust and the personal relationships that are built. 
Honestly. I think most CROs are highly capable of doing the work. They all can 
do it.  Many have been around for a long time and some have, of course, acquired 
others that have been around a long time. And so the subject matter experts, the 
experienced study directors and study teams are there at all times. So they can all 
do that. It's the communication, the support that you get. 
When describing capacity constraints and strategy in terms of deciding what work is 
outsourced to a CRO, Study Participant PharmBio2 explained the following: 
Our strategy right now is all of our GLP work is outsourced 100% because we 
don't have a GLP laboratory. So that's the first decision that we make point wise. 
The next piece is the specific capability at a specific CRO. And on top of that, the 
relationships or the experience we have with the specific study directors that are 
going to be running our studies. 
84 
 
Participant PharmBio2 continued: 
The relationships with individual scientists [i.e., study directors], in my view, is 
the most important and that kind of gets into trust. And my bedrock principle for 
working with CROs is communication. So communication is the number one 
reason why I'll stop using a provider. 
When asked to describe the strategy used in deciding what work is outsourced to a CRO, 
participant PharmBio4 stated the following: 
I think we go to places that have certain expertise. And part of that is it's learned 
over the years … that these partnerships develop … It’s experience with both the 
client liaisons and importantly the study directors. And so I think there's a comfort 
level that you get with people who over time learn, the specific way of writing 
things and what ends up happening is as that partnership develops, it costs us less 
time when we are reviewing reports, because we're talking the same language. 
Applications to Professional Practice 
In this study, I explored the experiences of key decision makers at 
pharmaceutical/biotech companies and CROs to describe and understand the 
collaborative approach to science and business that has fostered the strategic partnership 
paradigm. The specific business problem researched for this study was that some leaders 
of CRO and pharmaceutical/biotech companies lack strategies to develop strategic 
partnerships in the drug discovery and development process. The results and findings of 
this study are applicable to division leaders, client services personnel, procurement 
groups, program managers, and study directors that directly or indirectly make business 
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decisions that can impact a collaborative relationship between the service provider (CRO) 
and the client (pharmaceutical/biotech companies). 
Although some outsourced work by a pharmaceutical/biotech company to a CRO 
may be in its simplest form transactional, the evolution of a partnership into the 
intangible competency of a client relationship should be the business strategy for any 
company aiming to achieve effective value creation and competitive advantage. The 
comparative advantage theory expands on an organization’s tangible resources to include 
intangible competencies such as organizational culture, brand equity, knowledge, human 
capital (e.g., skills and knowledge of individual employees/teams), and relationships 
(e.g., with study teams and study directors) that enable the achievement of superior 
financial performance. This study highlighted an organization’s intangible resources and 
inherent competencies as determinants of success. The human capital factor and focus on 
relationships enable an organization to produce greater perceived benefits for similar 
costs. These perceived benefits are defined by how well a partnership evolves into an 
established relationship with a client. The relationship can be further strengthened by the 
trust established between the study director (CRO) and the pharmaceutical/biotech 
company. As suggested by participant CRO3, “A partnership is at the most simple level, 
it's where I think there is a higher level of intimacy. There's a higher level of trust, a 
higher level of just vulnerability.” 
Implications for Social Change 
The pharmaceutical drug discovery and development process is a daunting 
process that can usually take 10 to 15 years and cost billions of dollars. To identify one 
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effective and safe drug, millions of potential compounds and molecules are screened and 
for every 5,000 to 10,000 potential drugs evaluated, ultimately only one will receive 
approval from the FDA. To reduce the cost and time of drug development, most 
pharmaceutical/biotech companies strategically outsource much of their discovery and 
preclinical work/projects. By strategically outsourcing these activities, companies can 
depend on the expertise of the outsourcing partner (i.e., CRO), thereby reducing costs 
associated with having to introduce innovation. 
The results of this study suggest that focused attention on the client relationship as 
an evolution to the strategic partnership and a better understanding of how a client 
perceives trust and associated risk, can improve efficiency and therefore also reduce 
costs. These focused working relationships have the potential to help bring 
pharmaceutical drugs to market faster, cheaper, and with improved efficacy because of a 
clear understanding of expectations and the role each organization plays in the drug 
approval process, the assumed risk each organization assumes in the relationship, and the 
continued innovative approach to business and scientific collaboration. As stated by 
participant CRO3: 
Ultimately, that relationship is founded in the shared vision and mission of really 
having a benefit on all of our mutual customer, which is the patient who 
desperately, desperately deserves for a world class partnership. Because I think 
that the better we can truly partner, we will deliver a higher quality product to the 
patient and we will deliver it faster. And that will take time off of an already long 
drug development cycle, which saves lives. 
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By focusing on establishing lasting relationships, the CRO and pharmaceutical/biotech 
industries have the potential to shorten drug development timelines, further improving 
quality of life by providing a higher quality product to the patient, and ultimately saving 
lives. 
Recommendations for Action 
The key senior level decision-makers who participated in this study provided 
suggestions and insight on the strategies that CRO and pharmaceutical/biotech company 
leaders use to develop strategic relationships during the drug discovery and development 
process. Answers to the interview questions provided the basis for three overarching 
themes and opinions presenting business strategies focused on engagement between the 
CRO and pharmaceutical/biotech companies to create financially and scientifically 
mutually beneficial collaborations. The recommendations associated with the 3 
overarching themes of (a) defining a strategic/essential partnership, (b) understanding the 
benefit of building a relationship, and (c) the study director is an essential asset, are listed 






Recommendations for Action 
Theme Recommendations 
Defining a strategic/essential 
partnership 
• Evolve to more focused relationships beyond the ‘transaction’ 
• Establish key contacts 
• Maintain innovation 
• Treat each other with respect but with accountability 
Understanding the benefit of 
building a relationship 
• Establish trust 
• Maintain constant/consistent communication 
• Focus relationship on the SME/study director 
• Create a higher level of business intimacy 
• Understand inherent risk(s); perceived, individual, shared 
The study director is an essential 
asset 
• Encourage substantive business relationships with the client 
• Establish trust 
• Maintain constant/consistent communication 
 
These recommendations for action will be made available to business 
professionals within the pharmaceutical/biotech industries through online platforms, 
industry publications, and/or market research literature.  Additionally, these 
recommendations will be made available to the study participants and/or specific 
companies represented by the study participants. 
Recommendations for Further Research 
This qualitative multiple-case study included nine participants who were key 
senior level decision-makers in the pharmaceutical, biotech, and CRO industries (e.g., 
company presidents/vice presidents, CEO, and directors). Although I maintain that the 
multiple-case study research method was appropriate to draw conclusions from the lived 
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experiences of the study participants and the number of participants was adequate to 
represent the various industry sectors across a global representation of organizations 
sufficient to reach data saturation, there are aspects of the study that could benefit from 
further research and potentially more participants. The concept of trust in a business 
relationship can be further investigated to establish the expectations for building that 
trust. A longer duration evaluation of established business relationships can be conducted 
to determine actual time saved and reduced costs associated with the drug approval 
process. Additional research can be conducted to investigate the role of a pandemic on 
the partnership/relationship paradigm. Specifically, how the COVID-19 pandemic 
impacted CRO relationships with pharmaceutical/biotech companies racing to develop 
vaccines and treatments during 2020 and 2021 can be explored, and how/if relationships 
were made stronger/weaker by the expedited timing requirements can be investigated. 
Reflections 
The process of conducting this qualitative research study was informative and 
provided insight to a question I had early in my career. While my career and experience 
lend themselves to a very analytical and quantitative paradigm, the qualitative approach 
to case study research was an intensive and often challenging learning process. The 
substantial information that emerged from the semistructured interviews provided an 
interesting and comprehensive data set for answering the research question. 
Although I attempted to mitigate bias by contacting participants that I did not 
know personally or had previously worked with, it was very difficult to secure study 
participation. As a result, many of the study participants were colleagues that I knew and 
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had worked with previously in my career. Realizing I may have bias with these specific 
study participants, I adhered to preset guidelines and the interview protocol to ensure any 
biases and assumptions, real or perceived, were limited as suggested by Yin (2014). 
However, my previous relationships with some of the participants resulted in familiar 
conversation during the interviews. Nonetheless, I was able to manage the interactions so 
as not to influence the participants’ answers. 
Conclusion 
An organization’s intangible resources and inherent competencies are 
determinants of success. The evolution of a partnership into the intangible competency of 
a client relationship may likely define future business strategy for the industry. 
Understanding and improving existing company processes and evaluating strategic 
business relationships implemented between the pharmaceutical/biotech companies and 
CROs can result in business opportunities that are mutually beneficial. By understanding 
the importance of general business relationships, the intangible value of human capital 
competency, the relationships developed with clients by that human capital, and the 
significance that trust plays in how relationships are maintained and/or improved, 
business leaders can implement strategies that provide comparative business advantage 




Abdalla, M., Oliveira, L. G., Azevedo, C. E., & Gonzalez, R. K. (2018). Quality in 
qualitative organizational research: Types of triangulation as a methodological 
alternative. Administração: Ensino e Pesquisa, 19(1), 66-98. 
https://doi.org/10.13058/raep.2018.v19n1.578 
Almalki, S. (2016). Integrating quantitative and qualitative data in mixed methods 
research – challenges and benefits. Journal of Education and Learning, 5(3), 288-
296. https://doi.org/10.5539/jel.v5n3p288 
Amdur, R. J., & Bankert, E. A. (2011). Institutional review board. Member handbook 
(3rd ed.). Jones and Bartlett Publishers. 
Anney, V. N. (2014). Ensuring the quality of the findings of qualitative research: 
Looking at trustworthiness criteria. Journal of Emerging Trends in Educational 
Research and Policy Studies (JETERAPS), 5(2), 272-281. 
Antwi, S. K., & Hamza, K. (2015). Qualitative and quantitative research paradigms in 
business research: A philosophical reflection. European Journal of Business 
Management, 7(3), 217-225. 
Bailey, L. F. (2014). The origin and success of qualitative research. International Journal 
of Market Research, 56(2), 167-184. https://doi.org/10.2501/IJMR-2014-013 
Banerjee, T., & Martin, S. (2014). Pharmaceutical regulation and innovative 
performance: A decision-theoretic model. Managerial and Decision Economics, 
36(3), 177-190. https://doi.org/10.1002/mde.2659 
Bank of America Merrill Lynch. (2018, October). CRO industry update: “A rising tide 
92 
 
lifts all boats;” We are bullish on CROs [Unpublished industry overview]. 
Barney, J. B. (1991). Firm resources and sustained competitive advantage. Journal of 
Management, 17(1), 99-120. https://doi.org/10.1177/014920639101700108 
Barnham, C. (2015). Quantitative and qualitative research. International Journal of 
Market Research, 57(6), 837-854. https://doi.org/10.2501/IJMR-2015-070 
Baumann, C., Hoadley, S., Hamin, H., & Nugraha, A. (2017). Competitiveness vis-à-vis 
service quality as drivers of customer loyalty mediated by perceptions of 
regulation and stability in steady and volatile markets. Journal of Retailing and 
Consumer Services, 36, 62-74. https://doi.org/10.1016/j.jretconser.2016.12.005 
Beck, C. D. (2014). Antecedents of servant leadership: A mixed methods review. Journal 
of Leadership & Organizational Studies, 21, 299-314. 
https://doi.org/10.1177/1548051814529993 
Bekhet, A. K., & Zauszniewski, J. A. (2012). Methodological triangulation: An approach 
to understanding data. Nurse Researcher, 20(2), 40–43. 
http://doi.org/10.7748/nr2012.11.20.2.40.c9442 
Bernard, H. R. (2013). Social research methods: Qualitative and quantitative approaches 
(2nd ed.). Sage Publications. 
Bhattacharya, S., Dhiman, N., & Chaturvedi, J. (2016). Informed consent in human 
research. International Journal of Advanced Research in Biological Sciences, 
3(2), 181-186. 
BioCentury. (2020, March). CROs might be the engine that keeps preclinical research 
moving during COVID-19. https://www.biocentury.com/article/304734 
93 
 
Bloomberg, L. D., & Volpe, M. (2015). Completing your qualitative dissertation: A road 
map from beginning to end (3rd ed.). Sage. 
Bonacci, I., & Tamburis, O. (2016). Empowering openness: The case of CRO-related 
innovation networks in the Italian bio-pharmaceutical sector. International 
Journal of Learning and Intellectual Capital, 13(2/3), 184-201. 
https://doi.org/10.1504/IJLIC.2016.075697 
Brahma, S. S., & Chakraborty, H. (2011). From industry to firm resources: Resource-
based view of competitive advantage. IUP Journal of Business Strategy, 8(2), 
7-21. 
Brett, M. R. (2018). Cost leadership of differentiation? Applying Porter’s competitive 
strategies in ecotourism: A case study of Mkhuze Game Reserve. African Journal 
of Hospitality, Tourism and Leisure, 7(2). 
https://doaj.org/article/cbb44b0bdbcb4d05a0c31e98928e918d 
Brocair Partners. (2013, August). Overview of the CRO industry. 
http://www.brocair.com/pdfs/CRO_Industry_Report_8_12_2013.pdf 
Bryman, A. (2016). Social research methods (5th ed.). Oxford University Press 
Caiazza, R., Richardson, A., & Audretsch, D. (2015). Knowledge effects on 
competitiveness: from firms to regional advantage. Journal of Technology 
Transfer, 40, 899-909. https://doi.org/10.1007/s10961-015-9425-8 
Campbell, J., Quincy, C., Osserman, J., & Pedersen, O. (2013). Coding in-depth 
semistructured interviews: Problems of unitization and intercoder reliability and 




Carter, N., Bryant-Lukosius, D., DiCenso, A., Blythe, J., & Neville, A. J. (2014). The use 
of triangulation in qualitative research. Oncology Nursing Forum, 41(5), 545- 
547. https://doi.org/10.1188/14.onf.545-547 
Castillo-Montoya, M. (2016). Preparing for interview research: The interview protocol 
refinement framework. The Qualitative Report, 21(5), 811-831. 
Centers for Disease Control and Prevention. (2015, July 22). Our history – our story. 
http://www.cdc.gov/about/history/ourstory.htm 
Chan, Z. C. Y., Fung, Y., & Chien, W. (2013). Bracketing in phenomenology: Only 
undertaken in the data collection and analysis process. The Qualitative Report, 
18(30), 1-9. 
Chen, S. (2015). Customer value and customer loyalty: Is competition a missing link? 
Journal of Retailing and Consumer Services, 22, 107-116. 
https://doi.org/10.1016/j.jretconser.2014.10.007 
Cirillo, A., Mussolino, D., Saggese, S., & Sarto, F. (2018). Looking at the IPO from the 
“top floor”: A literature review. Journal of Management & Governance, 22, 661-
688. https://doi.org/10.1007/s10997-017-9397-1 
Clark, K., & Veale, B. (2018, May). Strategies to enhance data collection and analysis in 
qualitative research. Radiologic Technology, 89(5), 482-485. 
Cleary, M., Horsfall, J., & Hayter, M. (2014). Data collection and sampling in qualitative 




Constantinou, M., & Kuys, S. S. (2013). Physiotherapy students find guided journals 
useful to develop reflective thinking and practice during their first clinical 
placement: A qualitative study. Physiotherapy, 99(1), 49-55. 
https://doi.org/10.1016/j.physio.2011.12.002 
Corbin, J., & Strauss, A. (2015). Basics of qualitative research: Techniques and 
procedures for developing grounded theory (4th ed.) [Google Play version]. Sage 
Publications Inc.  
Credit Suisse. (2018, August). Contract research organizations (CROs). 
https://plus.credit-suisse.com/rpc4/ravDocView?docid=_XZP52AL-YxKG 
Creely, E. (2016, May 10). Understanding things from within. A Husserlian 
phenomenological approach to doing educational research and inquiring about 
learning. International Journal of Research & Method in Education, 41(1), 104-
122. https://doi.org/10.1080/1743727X.2016.1182482 
Dahan, G., & Shoham, A. (2014). Strategic orientations: Developing an integrative model 
of pioneering, entrepreneurial, and stakeholder orientations. Procedia – Social 
and Behavioral Sciences, 109, 758-762. 
https://doi.org/10.1016/j.sbspro.2013.12.540 
Denzin, N. K. (2012). Triangulation 2.0. Journal of Mixed Methods Research, 6(2), 80-
88. https://doi.org/10.1177?1558689812437186 
Drake, G. (2013). The ethical and methodological challenges of social work research 
with participants who fear retribution: To ‘do no harm.’ Qualitative Social Work, 
13(2), 304-319. https://doi.org/10.1177/1473325012473499 
96 
 
Emmel, N. (2013). Sampling and choosing cases in qualitative research: A realist 
approach. Sage. 
FDA Good Laboratory Practice for Nonclinical Laboratory Studies, 21 C.F.R. § 58.33 
(2020). 
Festel, G., Schicker, A., & Boutellier, R. (2010). Performance improvements in 
pharmaceutical R&D through new outsourcing models. Journal of Business 
Chemistry, 7(2), 89-96. 
Flick, U. (2015). Qualitative inquiry – 2.0 at 20? Development, trends, and challenges for 
the politics of research. Qualitative Inquiry, 21(7), 599-608. 
https://doi.org/10.1177/1077800415583296 
Flicke, U. (2014). An introduction to qualitative research (5th ed.). Sage Publications. 
Food and Drug Administration (FDA). (2016, July 5). FDA basics. 
http://www.fda.gov/AboutFDA/Transparency/Basics/default.htm  
Freeman, M., Gergen, K. J., & Josselson, R. (2015). The promises of qualitative inquiry. 
American Psychologist, 70, 1–9. 
Fusch, P. I., & Ness, L. R. (2015). Are we there yet? Data saturation in qualitative 
research. The Qualitative Report, 20(9), 1408-1416.  
Gantenbein, P., Kind, A., & Volonte, C. (2019). Individualism and venture capital: A 
cross-country study. Management International Review (MIR), 59(5), 741-777. 
https://doi.org/10.1007/s11575-019-00394-7 





Gibson, C. B. (2017). Elaboration, generalization, triangulation, and interpretation: On 
enhancing the value of mixed method research. Organizational Research 
Methods, 20(2), 193-223. https://doi.org/10.1177/1094428116639133 
Gibson, W., Webb, H., & Lehn, V. D. (2014). Analytic affordance: Transcripts as 
conventionalised systems in discourse studies. Sociology, 48(4), 780-794. 
https://doi.org/10.1177/0038038514532876 
Gorylev, A. I., Tregubova, N. D., & Kurbatov, S. V. (2015). Comparative advantages and 
limitations of qualitative strategy of comparison as applied to Russian cases of 
Perestroika period's representation in history textbooks. Asian Social Science, 
11(3), 218-223. https://doi.org/10.5539/ass.v11n3p218 
Grady, C. (2015). Enduring and emerging challenges of informed consent. The New 
England Journal of Medicine, 372(9), 855-862. 
https://doi.org/10.1056/NEJMra1411250 
Green, G. (2009). The CRO market outlook to 2014: Emerging markets, leading players 
and future trends. Business Insights, 1-167. 
https://www.slideshare.net/ReportLinker/the-cro-market-outlook-emerging-
markets-leading-players-and-future-trends 
Gupta, S., Woodside, A., Dubelaar, C., & Bradmore, D. (2009). Diffusing knowledge-
based core competencies for leveraging innovation strategies: Modeling 
outsourcing to knowledge process organizations (KPOs) in pharmaceutical 




Harper, M., & Cole, P. (2012). Member checking: Can benefits be gained similar to 
group therapy? The Qualitative Report, 17, 510–517. 
Harris Williams. (2014, April). Contract research organization industry overview. 
http://www.harriswilliams.com/sites/default/files/industry_reports/2014.4.17_cont
ract_research_organizations.pdf 
Heale, R., & Forbes, D. (2013). Understanding triangulation in research. Evidence Based 
Nursing, 16(4), 98-98. https://doi.org/10.1136/eb-2013-101494 
Henderson, L. (2013). The state of CRO and sponsor relationships. Applied Clinical 
Trials, 22(10), 26-29. https://www.appliedclinicaltrialsonline.com/view/state-cro-
and-sponsor-relationships 
Huang, K., Dyerson, R., Wu, L., & Harindranath, G. (2015). From temporary competitive 
advantage to sustainable competitive advantage. British Journal of Management, 
26(4), 617-636. https://doi.org/10.1111/1467-8551.12104 
Hunt, S. D., & Morgan, R. M. (1995). The comparative advantage theory of competition. 
Journal of Marketing, 59(2), 1-15. https://doi.org/10.2307/1252069 
Hussein, A. (2009). The use of triangulation in social sciences research: Can qualitative 







Hyett, N., Kenny, A., & Dickson-Swift, V. (2014). Methodology or method? A critical 
review of qualitative case study reports. International Journal of Qualitative 
Studies on Health and Well-Being, 9(1). https://doi.org/10.3402/qhw.v9.23606 
Irvine, A., Drew, P., & Sainsbury, R. (2013). ‘Am I not answering your questions 
properly?’ Clarification, adequacy and responsiveness in semi-structured 
telephone and face-to-face interviews. Qualitative Research, 13(1), 87-106. 
https://doi.org/10.1177/1468794112439086 
Jefferies. (2014, May). Pharmaceutical services. Part II: Growing pie, unless someone 
eats a big slice. https://javatar.bluematrix.com 
Jefferies. (2015, July). Pharmaceutical services. Accelerating growth; Managing glass 
reveals pockets of opportunity. https://javatar.bluematrix.com/pdf/wnYTZHNc 
Jeng, D. J., & Pak, A. (2016). The variable effects of dynamic capability by firm size: 
The interaction of innovation and marketing capabilities in competitive industries. 
International Entrepreneurship and Management Journal, 12(1), 115-130. 
https://doi.org/10.1007/s11365-014-0330-7 
Jones, S. M. (2014). Making me feel comfortable developing trust in the nurse for 
Mexican Americans. Western Journal of Nursing Research, 37(11), 1423-1440. 
https://doi.org/10.1177/0193945914541519 
Kay, J. (2018). Theories of the firm. International Journal of the Economics of Business, 
25(1), 11-17. https://doi.org/10.1080/13571516.2017.1402468 
Kelly, K. (2016). A different type of lighting research – A qualitative methodology. 




Klag, M., & Langley, A. (2013). Approaching the conceptual leap in qualitative research. 
International Journal of Management Reviews, 15(2), 149-166. 
https://doi.org/10.1111/j.1468-2370.2012.00349.x 
Koerber, A., & McMichael, L. (2008). Qualitative sampling methods: A primer for 
technical communicators. Journal of Business and Technical Communication, 
22(4), 454-473. https://doi.org/10.1177/1050651908320362 
Leung, L. (2015). Validity, reliability, and generalizability in qualitative research. 
Journal of Family Medicine & Primary Care, 4(3), 324-327. 
https://doi.org/10.4103/2249-4863.161306 
Lin, H., & Darnall, N. (2015). Strategic alliance formation and structural configuration. 
Journal of Business Ethics, 127, 549-564. https://doi.org/10.1007/s10551-014-
2053-7 
Lincoln, Y. S., & Guba, E. G. (1985). Naturalistic inquiry. Sage. 
Liu, F., & Huang, T. (2017). The influence of collaborative competence and service 
innovation on manufacturers’ competitive advantage. Journal of Business & 
Industrial Marketing, 33(4), 466-477. https://doi.org/10.1108/JBIM-12-2016-
0294 
Lub, V. (2015). Validity in qualitative evaluation: Linking purpose, paradigms, and 
perspectives. International Journal of Qualitative Methods, 14(5), 1-8. 
https://doi.org/10.1177/1609406915621406 
Marrone, S. R. (2016). Informed consent examined within the context of culturally 
101 
 
congruent care: An interprofessional perspective. Journal of Transcultural 
Nursing, 27(4), 342-348. https://doi.org/10.1177/1043659615569537 
Marshall, C., & Rossman, G. (2016). Designing qualitative research (6th ed.). Sage. 
Martin, F., Benjamin, A., MacLean, R., Hollinshead, D., & Landqvist, C. (2017). Use of 
a collaborative tool to simplify the outsourcing of preclinical safety studies: an 
insight into the AstraZeneca-Charles River Laboratories strategic relationship. 
Drug Discovery Today, 22(12), 1754-1759. 
https://doi.org/10.1016/j.drudis.2017.08.007 
Michelino, F., Lamberti, E., Cammarano, A., & Caputo, M. (2015). Measuring open 
innovation in the bio-pharmaceutical industry. Creativity & Innovation 
Management, 24(1), 4-28. https://doi.org/10.1111/caim.12072 
Miller, J. (2010). The Lilly way. Pharmaceutical Technology Europe, 22(5), 12-14. 
Miller, J. (2013). The state of outsourcing partnerships. Pharmaceutical Technology, s6-
s10. https://www.pharmtech.com/view/state-outsourcing-partnerships 
Miller, J. (2017). The tide stays high: Robust venture capital investment gives CDMOs 
and CROs a positive outlook for 2017. Pharmaceutical Technology, 41(1), 22-24. 
https://www.pharmtech.com/view/tide-stays-high 
Mohajan, H. K. (2018). Qualitative research methodology in social sciences and related 
subjects. Journal of Economic Development, Environment and People, 7(1), 23-
48. https://doi.org/10.26458/jedep.v7i1.571 
Morse, J. M. (2015). Critical analysis of strategies for determining rigor in qualitative 




Morse, J. M., & Coulehan, J. (2015). Maintaining confidentiality in qualitative 
publications. Qualitative Health Research, 25(2), 151-152. 
https://doi.org/10.1177/1049732314563489 
Moustakas, C. E. (1994). Phenomenological research methods. Sage. 
Muswazi, M., & Nhamo, E. (2013). Note taking: A lesson for novice qualitative 
researchers. Journal of Research and Method in Education, 2(3), 13-17. 
National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research. (1979). The Belmont report: Ethical principles and 
guidelines for the protection of human subjects of research. Washington, DC: 
Department of Health and Human Services. http://www.hhs.gov/ohrp/regulations-
and-policy/belmont-report/index.html 
National Institutes of Health. (n.d.). About NIH. http://nih.gov/about/  
Njie, B., & Asimiran, S. (2014). Case study as a choice in qualitative 
methodology.  IOSR Journal of Research & Method in Education, 4(3), 35–40. 
http://doi.org/10.9790/7388-04313540 
O’Grady, E. (2016). Research as a respectful practice: an exploration of the practice of 
respect in qualitative research. Qualitative Research in Education, 5(3), 229-254. 
https://doi.org/10.17583/qre.2016.2018 
O’Reilly, M., & Parker, N. (2013) Unsatisfactory saturation: A critical exploration of the 
notion of saturated sample sizes in qualitative research. Qualitative Research 
Journal, 13(2), 190-197. https://doi.org/10.1177/1468794112446106 
103 
 
Otola, I., Ostraszewska, Z., & Tylec, A. (2013). New directions of development of 
resource-based view in creating a competitive advantage. Business Management 
Dynamics, 3(2), 26–33. 
Palinkas, L. A., Horwitz, S. M., Green, C. A., Wisdom, J. P., Duan, N., & Hoagwood, K. 
(2015). Purposeful sampling for qualitative data collection and analysis in mixed 
method implementation research. Administration and Policy in Mental Health, 
42(5), 533-544. https://doi.org/10.1007/s10488-013-0528-y 
Pappa, D. D., Stergioulas, L. K., & Telonis, P. (2009). The role of knowledge 
management in the pharmaceutical enterprise. International Journal of 
Technology Management, 47(1-3), 127-144. 
https://doi.org/10.1504/IJTM.2009.024118 








Parrett, A. (2013). Challenging the value of strategic partnerships in clinical trial 
outsourcing. Applied Clinical Trials, 22(4), 30-33.  
Patil, P. S. (2016). Drug discovery and ADMET process: A review. International Journal 
104 
 
of Advanced Research in Biological Sciences, 3(7), 181-192. 
http://www.ijarbs.com/cissuejuly2016.html 
Patterson, E. S., Murray, J., Park, S., Sanders, E. B., Li, J., Umar, R., . . . Lavender, S. A. 
(2014). Barriers to infection control due to hospital patient room factors: A 
secondary analysis of focus group and interview transcripts. Proceedings of the 
Human Factors and Ergonomics Society Annual Meeting, 58(1), 1266-1270. 
https://doi.org/10.1177/1541931214581264 
Patton, M. (2015). Qualitative research and evaluation methods: Integrating theory and 
practice (4th ed.). Sage. 
Peredaryenko, M. S., & Krauss, S. E. (2013). Calibrating the human instrument: 
Understanding the interviewing experience of novice qualitative researchers. The 
Qualitative Report, 18(43), 1-17. 
Peteraf, M. A., & Barney, J. B. (2003). Unraveling the resource-based tangle. Managerial 
and Decision Economics, 24(4), 309-323. https://doi.org/10.1002/mde.1126 
Porter, M. E. (1980). Competitive strategy: Techniques for analyzing industries and 
competitors. The Free Press. 
Porter, M. E. (1985). Competitive advantage: Creating and sustaining superior 
performance. The Free Press. 
Porter, M. E. (1991). Towards a dynamic theory of strategy. Strategic Management 
Journal, 12(S2), 95-117. https://doi.org/10.1002/smj.4250121008 




Rahman, M., Angeles Rodriguez-Serrano, M., & Lambkin, M. (2019). Advertising 
efficiency and profitability: Evidence from the pharmaceutical industry. Industrial 
Marketing Management, 89, 619-629. 
https://doi.org/10.1016/j.indmarman.2019.02.001 
Rapport, F., Clement, C., Doel, M. A., & Hutchings, H. A. (2015). Qualitative research 
and its methods in epilepsy: Contributing to an understanding of patients' lived 
experiences of the disease. Epilepsy & Behavior, 45, 94-100. 
https://doi.org/10.1016/j.yebeh.2015.01.040 
Reinecke, J., Arnold, D. G., & Palazzo, G. (2016). Qualitative methods in business ethics, 
corporate responsibility, and sustainability research. Business Ethics Quarterly, 
26(4), 13-22. https://doi.org/10.1017/beq.2016.67 
Ritchie, J., Lewis, J., McNaughton Nicholls, C., & Ormston, R. (Eds.) (2014). Qualitative 
research practice: A guide for social science students & researchers. Sage. 
Robinson, O. C. (2013). Qualitative research in psychology sampling in interview-based 
qualitative research: A theoretical and practical Guide. Qualitative Research in 
Psychology, 11(1), 37–41. http://doi.org/10.1080/14780887.2013.801543 
Rodrigues, R. J., Antony, J., Krishnamurthy, S., Shet, A., & De Costa, A. (2013). What 
do I know? Should I participate? Considerations on participation in HIV related 
research among HIV infected adults in Bangalore, South India. Plos ONE, 8(2), 
1-8. https://doi.org/10.1371/journal.pone.0053054 
Rule, P., & John, V. M. (2015). A necessary dialogue theory in case study research. 




Rumelt, R. P. (1991). How much does industry matter? Strategic Management Journal, 
12(3), 167-185. https://doi.org/10.1002/smj.4250120302 
Salavou, H. E. (2015). Competitive strategies and their shift to the future. European 
Business Review, 27(1), 80-99. 
Sandelowski, M. (2008). Theoretical saturation. In L. M. Given, (Ed.), The SAGE 
encyclopedia of qualitative research methods, Vol. 2 (pp. 875-876). Sage. 
Saunders, B., Kitzinger, J., & Kitzinger, C. (2015). Anonymising interview data: 
Challenges and compromise in practice. Qualitative Research, 15(5), 616-632. 
https://doi.org/10.1177/1468794114550439 
Saunders, B., Sim, J., Kingstone, T., Baker, S., Waterfield, J., Bartlam, B., Burroughs, H., 
& Jinks, C. (2018). Saturation in qualitative research: Exploring its 
conceptualization and operationalization. Quality & Quantity, 52(4), 1893-1907. 
https://doi.org/10.1007/s11135-017-0574-8 
Schendel, D. (1994). Competitive organizational behavior: Toward an organizationally: 
based theory of competitive advantages. Strategic Management Journal, 15(S1), 
1-4. https://doi.org/10.1002/smj.4250150901 
Simon, M., & Goes, J. (2015). Assumptions, limitations and delimitations, and scope of 
the study. Dissertation and scholarly research: Recipes for success. http://www. 
dissertationrecipes.com/assumptions-limitations-delimitations/ 
Smollan, R. K. (2015). The personal costs of organizational change: A qualitative study. 




Snyder, H. (2019). Literature review as a research methodology: An overview and 
guidelines. Journal of Business Research, 104, 333-339. 
https://doi.org/10.1016/j.jbusres.2019.07.039 
Soloducho-Pelc, L. (2014). Competitive advantage: The courage in formulating 
objectives and expansiveness of a strategy. Procedia – Social and Behavioral 
Sciences, 150(2014), 271-280. https://doi.org/10.1016/j.sbspro.2014.09.058 
Sorsa, M. A., Kiikkala, I., & Astedt-Kurki, P. (2015). Bracketing as a skill in conducting 
unstructured qualitative interviews. Nurse Researcher (2014+), 22(4), 8-12. 
https://doi.org/10.7748/nr.22.4.8.e1317 
Sousa, D. (2014). Validation in qualitative research: General aspects and specificities of 
the descriptive phenomenological method. Qualitative Research in Psychology, 
11(2), 211-227. https://doi.org/10.1080/14780887.2013.853855 
Speer, S. A., & Stokoe, E. (2014). Ethics in action: Consent-gaining interactions and 
implications for research practice. British Journal of Social Psychology, 53(1), 
54–73. https://doi.org/10.1111/bjso.12009 
Strauss, A., & Corbin, J. (1998). Basics of qualitative research: Techniques and 
procedures for developing grounded theory (2nd ed.). Sage Publications. 
Sugar, W. (2014). Development and formative evaluation of multimedia case studies for 
instructional design and technology students. TechTrends, 58, 36-52. 
https://doi.org/10.1007/s11528-014-0785-z 
Taverno Ross, S. E., & Francis, L. A. (2016). Physical activity perceptions, context, 
108 
 
barriers, and facilitators from a Hispanic child’s perspective. International 
Journal of Qualitative Studies on Health and Well-being, 11(1), 1-10. 
https://doi.org/10.3402/qhw.v11.31949 
Tene, O., & Polonetsky, J. (2016). Beyond IRBs: Ethical guidelines for data research. 
Washington and Lee Law Review Online, 72(3), 458. 
http://scholarlycommons.law.wlu.edu/wlulr-online/vol72/iss3/7 
Tracy, S. J. (2013). Qualitative research methods. Wiley-Blackwell. 
Tuohy, D., Cooney, A., Dowling, M., Murphy, K., & Sixsmith, J. (2013). An overview of 
interpretive phenomenology as a research methodology. Nurse Researcher, 20(6), 
17-20. https://doi.org/10.7748/nr2013.07.20.6.17.e315 
Venkatesh, V., Brown, S. A., & Bala, H. (2013). Bridging the qualitative – quantitative 
divide: Guidelines for conducting mixed methods research in information 
systems. MIS Quarterly, 37, 21–54. 
Wang, H. (2014). Theories for competitive advantage. In H. Hasan (Ed.), Being practical 
with theory: A window into business research (pp. 33-43). 
http://eurekaconnection.files.wordpress.com/2014/02/p-33-43-theories-of-
competitive-advantage-theori-ebook_finaljan2014-v3.pdf 
Whalen, P., Uslay, C., Pascal, V., Omura, G., McAuley, A., Kasouf, C. J., Jones, R., 
Hultman, C., Hills, G., Hansen, D. J., Gilmore, A., Giglierana, J., Eggers, F., & 
Deacon, J. (2016). Anatomy of competitive advantage: toward a contingency 




William Blair & Company. (2018). Pharmaceutical outsourcing & services. CRO 
industry update: Results from spring 2018 survey of biopharmaceutical sponsors. 
https://williamblairlibrary.bluematrix.com 
William Blair & Company. (2020). Pharmaceutical outsourcing & services. CRO 
industry update: Results from fall 2020 survey of biopharmaceutical sponsors. 
https://williamblairlibrary.bluematrix.com 
Wilson, R., Kieburtz, K., Holloway, R. G., & Kim, S. H. (2014). Evidence-based 
research ethics and determinations of engagement in research. IRB: Ethics & 
Human Research, 36(2), 10-13. 
http://www.thehastingscenter.org/Publications/IRB/ 
Yerkic-Husejnovic, B. (2017). Strategies in outsourcing R&D processes to maintain 
market competitiveness (Doctoral Study). 
http://scholarworks.waldenu.edu/dissertations 
Yilmaz, K. (2013). Comparison of quantitative and qualitative research traditions: 
Epistemological, theoretical, and methodological differences, European Journal 
of Education, 48(2), 311-325. https://doi.org/10.1111/ejed.12014 
Yin, R. K. (2014). Case study research: Design and methods (5th ed.). Sage Publications. 
Yin, R. K. (2016). Qualitative research from start to finish (2nd ed.). The Guilford Press. 
Zitomer, M. R., & Goodwin, D. (2014). Gauging the quality of qualitative research in 
adapted physical activity. Adapted Physical Activity Quarterly, 31(3), 193-218. 
https://doi.org/10.1123/apaq.2013-0084 
Zohrabi, M. (2013). Mixed method research: Instruments, validity, reliability and 
110 
 




Appendix A: Interview Protocol 
Interview: Key nonclinical pharmaceutical industry decision makers’ insight describing 
the attitudes and experiences they have toward strategic business collaborations with each 
other, what risk responsibilities service providers (i.e., Contract Research Organizations) 
assume in a scientific/business strategic partnership, and how those collaborations have 
influenced the pharmaceutical research industry 
Protocol:  
A. The study and a general overview will be provided via a formal email and/or 
telephone conversation.  
B. The subsequent formal telephone or Skype interviews will begin with introductions 
followed by an overview of the study. 
C. Appreciation will be conveyed to each participant for agreeing to contribute in the 
study, and each participant will be assured of the confidentiality of our conversations. 
D. Each participant will be assigned an identifying code to protect his or her anonymity 
and this identifying code will be defined at the beginning of each interview and 
subsequent audio-recording.  
E. The participants will be instructed as to the following:  
1. Each participant will be asked to provide responses to 10 open-ended interview 
questions (the interview should last approximately 30 to 45-minutes). 
2. Each participant will be informed that they will be digitally (audio) recorded during 
the interview to ensure accuracy of data and their responses. 
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3. Each participant will be asked to share their lived experiences and/or perceptions 
regarding strategic business collaborations, what risk responsibilities service 
providers assume in a scientific/business strategic partnership, and how those 
collaborations have influenced the pharmaceutical research industry.  
F. Member-checking will be explained to each participant and a follow-up member-
checking interview will be scheduled to review data findings to ensure accuracy of 
the data and to ensure that it is a correct representation of the participants’ 
perceptions.  





Appendix B: Interview Questions 
Appendix B lists the open-ended interview questions used to understand what risk 
responsibilities service providers (i.e., Contract Research Organizations) assume in a 
scientific/business strategic partnership with a pharmaceutical/biotech company client.  
The following are the interview questions:  
1. What do you think the role of a CRO is in a strategic partnership during drug 
discovery and development? 
2. What is your strategy in terms of deciding what work (i.e., projects, programs, 
etc.) is outsourced to a CRO? 
3. How would you describe a strategic partnership with a CRO during the drug 
development process? 
4. Describe the most important factors that influence your selection of a strategic 
partner (ranked from most important to least important). 
5. What do you think currently differentiates the preclinical CRO(s) that you 
have strategic partnership(s) with and were similar strategies used to develop 
that/those relationship(s)? 
6. As strategic partnerships evolve, what are your concerns considering your 
current partnerships/relationships and the expectations you have now and in 
the future? 
7. How do you measure the financial success of your outsourcing (strategic 
partnership, if applicable) project(s)? 
8. How do you assess and manage outsourcing (strategic partnership) risks? 
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9. Describe the risk-sharing responsibilities/assumptions you currently have with 
your outsourcing partner. 
10. What else can you add regarding strategies service providers (i.e., Contract 
Research Organizations) and pharmaceutical/biotech companies use to 
develop strategic partnerships during the drug discovery and development 
process? 
